<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1306233791
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEVANAC EYE DROP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NEPAFENAC
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ocular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="S.A. Alcon Couvreur N.V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            S.A. Alcon Couvreur N.V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01BC10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NEVANAC contains the active substance nepafenac, and belongs to a group of medicines called nonsteroidal anti-inflammatory drugs (NSAIDs).</p><p>&nbsp;</p><p>NEVANAC is to be used by adults:</p><p><s>-&nbsp;</s>to prevent and relieve eye pain and inflammation<strong> </strong>following cataract surgery on the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to reduce the risk of macular oedema (swelling in the back of the eye) following cataract surgery on the eye in diabetic patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use NEVANAC</strong></p><p>-&nbsp;&nbsp; if you are allergic to nepafenac or any of the other ingredients of this medicine (listed in section 6),&nbsp;</p><p>-&nbsp;&nbsp; if you are allergic to other nonsteroidal anti-inflammatory drugs (NSAID)</p><p>-&nbsp;&nbsp; if you have experienced asthma, skin allergy, or intense inflammation in your nose when using other NSAIDs. Examples of NSAIDs are: acetylsalicylic acid, ibuprofen, ketoprofen, piroxicam, diclofenac.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using NEVANAC:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you bruise easily or have bleeding problems<strong> </strong>or have had them in the past.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any other eye disorder (e.g. an eye infection) or if you are using other medicines in the eye (especially topical steroids).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have rheumatoid arthritis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had repeated eye surgery<strong> </strong>within a short period of time.</p><p>&nbsp;</p><p>Avoid sunlight during treatment with NEVANAC</p><p><strong>&nbsp;</strong></p><p>Wearing contact lenses is not recommended after cataract surgery. Your doctor will advise you when you can use contact lenses again (see also &ldquo;NEVANAC contains benzalkonium chloride&rdquo;)</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children and adolescents below 18 years old because the safety and efficacy in this population has not been established.</p><p>&nbsp;</p><p><strong>Other medicines and NEVANAC</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p><strong>&nbsp;</strong></p><p>NEVANAC can affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma.</p><p>&nbsp;</p><p>Also tell your doctor if you are taking medicines that reduce blood clotting (warfarin) or other NSAIDs. They may increase the risk of bleeding.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant, or might get pregnant, talk to your doctor before you use NEVANAC. Women who may become pregnant are advised to use effective contraception during NEVANAC treatment. The use of NEVANAC is not recommended during pregnancy. Do not use NEVANAC unless clearly indicated by your doctor.</p><p>&nbsp;</p><p>If you are breast-feeding,<strong> </strong>NEVANAC<strong> </strong>may pass into your milk. However, no effects on suckling children are anticipated. NEVANAC can be used during breastfeeding.</p><p>&nbsp;</p><p>If you are pregnant or breastfeeding , think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist&nbsp; for advice before taking&nbsp; this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Do not drive or use machines until your vision is clear. You may find that your vision is blurred for a time just after using NEVANAC.&nbsp;</p><p>&nbsp;</p><p><strong>NEVANAC contains benzalkonium chloride</strong></p><p>The preservative in NEVANAC, bezalkonium chloride, can discolour soft lenses and may cause eye irritation and corneal side effects (eye surface problems). If your doctor informs you that you can use contact lenses again, please note that you should remove them prior to application and wait at least 15 minutes before reinsertion.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Only use NEVANAC for your eyes. Do not swallow or inject.</p><p>&nbsp;</p><p><strong>The recommended dose is</strong></p><p>One&nbsp;drop in the affected eye or eyes, three&nbsp;times a day - morning, midday, and evening. Use at the same time each day.</p><p>&nbsp;</p><p><strong>When to take and for how long </strong></p><p>Begin 1&nbsp;day before cataract surgery. Continue on the day of surgery. Then use it for as long as your doctor tells you to. This may be up to 3 weeks (to prevent and relieve eye pain and inflammation) or 60&nbsp;days (to prevent the development of macular oedema) after your operation.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>How to use</strong></p><p>Wash your hands<strong> </strong>before you start.</p><table border="1" align="left" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center; width:249px"><img src="data:image/png;base64,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" alt="" width="120" height="116" vspace="0" hspace="0" border="0" style="width:120px;height:116px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></td><td style="text-align:center; width:250px"><img alt="" width="120" height="116" vspace="0" hspace="0" border="0" style="width:120px;height:116px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="data:image/png;base64,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" /></td></tr><tr><td style="text-align:center; width:249px">1</td><td style="text-align:center; width:250px">2</td></tr></tbody></table><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="MSPhotoEd.3" ShapeID="_x0000_i1026"
  DrawAspect="Content" ObjectID="_1653833038">
 </o:OLEObject>
</xml><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake well before use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Twist off the bottle cap.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After cap is removed, if tamper evident snap collar is loose, remove before using product.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the bottle, pointing down, between your thumb and fingers.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tilt your head back.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pull down your lower eyelid with a clean finger, until there is a &lsquo;pocket&rsquo; between the eyelid and your eye.&nbsp; The drop will go in here (picture&nbsp;1).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bring the bottle tip close to the eye.&nbsp; Do this in front of a mirror if it helps.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not touch your eye or eyelid, surrounding areas or other surfaces with the dropper.&nbsp; It could infect the drops.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently press on the base of the bottle to release one&nbsp;drop of NEVANAC at a time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not squeeze the bottle: it is designed so that a gentle press on the bottom is all that it needs (picture 2).</p><p>&nbsp;</p><p>If you use drops in both eyes, repeat the steps for your other eye. Close the bottle cap firmly immediately after use.</p><p>&nbsp;</p><p>If a drop misses your eye, try again.</p><p>&nbsp;</p><p>If you are using other eye drops, wait at least five minutes between using NEVANAC and the other drops.</p><p>&nbsp;</p><p><strong>If you use more NEVANAC than you should</strong></p><p>Rinse your eye out with warm water. Do not put in any more drops until it is time for your next regular dose.</p><p>&nbsp;</p><p><strong>If you forget to use NEVANAC</strong></p><p>Use a single dose as soon as you remember. If it is almost time for the next dose, leave out the missed dose and continue with the next dose of your regular routine. <strong>Do not</strong> use a double dose to make up for a missed dose<strong>. </strong><strong>Do not</strong> use more than one&nbsp;drop in the affected eye(s) 3&nbsp;times daily.</p><p>&nbsp;</p><p><strong>If you stop using NEVANAC </strong></p><p>Do not stop using NEVANAC without speaking to your doctor first. You can usually carry on using the drops, unless you experience serious side effects. If you are worried talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects although not everybody gets them.</p><p>&nbsp;</p><p>There may be a higher risk of corneal side effects (eye surface problems) if you have:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; complicated eye surgery</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; repeated eye surgery within a short period of time</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain disorders of the surface of the eye, such as inflammation or dry eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain general disease, such as diabetes or rheumatoid arthritis</p><p>&nbsp;</p><p>Contact your doctor immediately if your eyes become more red or more painful whilst using the drops. This may be a result of inflammation on the eye surface with or without loss or damage of cells or an inflammation of the coloured part of the eye (iritis). These side effects have been observed in up to 1 in 100 people.</p><p>&nbsp;</p><p>The following side effects have also been observed with NEVANAC 1 mg/ml eye drops, suspension or NEVANAC 3 mg/ml eye drops, suspension, or both.</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong></p><p><em>(may affect up to 1&nbsp;in 100&nbsp;people) </em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Effects in the eye: </strong>eye surface inflammation with or without loss or damage of cells, foreign body sensation in the eyes, eyelid crusting or drooping.<br />&nbsp;</p><p><strong>Rare side effects </strong></p><p><em>(may affect up to 1&nbsp;in 1,000&nbsp;people) </em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Effects in the eye</strong>: iris inflammation, eye pain, eye discomfort,&nbsp; dry eye, eyelid swelling, eye irritation, itchy eye, eye discharge, allergic conjunctivitis (eye allergy), increased tear production, deposits on the eye surface, fluid or swelling at the back of the eye, eye redness.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General side effects: </strong>dizziness, headache, allergic symptoms (eyelid allergic swelling), nausea, skin inflammation, redness and itching.</p><p>&nbsp;</p><p><strong>Side effects with f</strong><strong>requency not known</strong> (cannot be estimated from the available data)</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Effects in the eye</strong>: damage on the surface of the eye such as thinning or perforation, impaired healing of the eye, eye surface scar, clouding, reduced vision, eye swelling, blurred vision.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General side effects: </strong>vomiting, increased blood pressure.</p><p><em><u>&nbsp;</u></em></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out<strong> </strong>of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Throw away the bottle 4&nbsp;weeks after first opening, to prevent infections. Write the date of opening on the bottle and carton label in the space provided.</p><p>&nbsp;</p><p>Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use.&nbsp; These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is nepafenac. One&nbsp;ml of suspension contains 1&nbsp;mg of nepafenac.</li></ul><p><strong>&nbsp;</strong></p><ul><li>The other ingredients are<strong> </strong>benzalkonium chloride (see section 2), carbomer, disodium edetate, mannitol, purified water, sodium-chloride and tyloxapol.<br />Tiny amounts of sodium hydroxide and/or hydrochloric acid are added to keep acidity levels (pH&nbsp;levels) normal.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NEVANAC is a liquid (light yellow to light orange suspension) supplied in a pack containing one 5 ml plastic bottle with a screw cap.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by EMA in : 05/17
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار نيفاناك على المادة الفعالة نيبافيناك وينتمي لفئة من الأدوية تُسمى بمضادات الالتهاب غير الستيرويدية (NSAIDs).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار نيفاناك من قبل البالغين:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمنع وتخفيف آلام والتهابات العين بعد جراحة إعتام عدسة العين (المياه البيضاء) التي تجرى بالعين.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>للحد من خطر الإصابة بالوذمة البقعية (تورم في الجزء الخلفي من العين) بعد جراحة إعتام عدسة العين (المياه البيضاء) التي تجرى في العين في المرضى المصابين بالسكري.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال عقار نيفاناك</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه نيبافيناك أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه مضادات الالتهاب غير الستيرويدية الأخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بالربو، حساسية الجلد أو التهاب شديد بالأنف عند استخدام مضادات التهاب غير ستيرويدية أخرى. أمثلة مضادات الالتهاب غير الستيرويدية هي: حمض أسيتيل الساليسيليك، إيبوبروفين، كيتوبروفين، بيروكسيكام، ديكلوفيناك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استخدام عقار نيفاناك</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة) قبل استخدام عقار نيفاناك في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تصاب بالكدمات بسهولة أو إذا كانت لديك مشاكل نزيف أو إذا كنت قد أصبت بها سابقًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك أي اضطرابات أخرى بالعين (على سبيل المثال:&nbsp; عدوى بالعين) أو إذا كنت تستخدم أدوية أخرى بالعين (لا سيما الستيرويدات الموضعية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت مصابًا بمرض السُّكَّرِي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت مصابًا بالتهاب المفاصل الروماتويدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت لجراحات متكررة بالعين في غضون فترة زمنية قصيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تجنب أشعة الشمس أثناء العلاج بعقار نيفاناك</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا يُنصح بارتداء العدسات اللاصقة بعد جراحة إعتام عدسة العين (المياه البيضاء). سيخبرك طبيبك متى يمكنك معاودة استخدام العدسات اللاصقة (انظر أيضًا قسم: &quot;يحتوي عقار نيفاناك على كلوريد البنزالكونيوم&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. الأطفال والمراهقون</strong></p><p dir="RTL">لا يُعطى هذا الدَّواء للأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا؛ نظرًا لأنَّه لم يثبت أمانه وفعاليته في هذه الشَّريحة من المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د. التداخلات الدوائية من أخذ هذا العقار مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يُؤثر عقار نيفاناك في عمل الأدوية الأخرى التي تستخدمها أو يتأثر عمله بها، بما في ذلك قطرات العين المستخدمة لعلاج الجلوكوما (المياه الزرقاء).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى أيضًا إخبار الطبيب إذا كنت تتناول أدوية تحد من تجلط الدَّم (وارفارين) أو مضادات التهاب غير ستيرويدية أخرى. قد تزيد من خطر الإصابة بنزيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو قد تصبحين حاملًا، تحدَّثي إلى طبيبكِ قبل استخدام عقار نيفاناك. تُنصح السيدات اللاتي قد يصبحن حوامل باستخدام وسيلة منع حمل فعالة أثناء العلاج بعقار نيفاناك. لا يُوصى باستخدام عقار نيفاناك أثناء الحَمْل. لا تستخدمي عقار نيفاناك ما لم يُشر طبيبك بوضوح بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ مرضعًا، فقد ينتقل عقار نيفاناك إلى لبن الثدي لديكِ. مع ذلك، لا يُتوقع أن يكون للعقار تأثير على الرُّضع. يمكن استعمال عقار نيفاناك أثناء الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و. تأثير عقار نيفاناك على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تمارس القيادة أو تستخدم الآلات حتى تصبح الرؤية لديك واضحة. قد تجد أنَّ الرؤية لديك غير واضحة لبعض الوقت بعد استخدام عقار نيفاناك.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ز. يحتوي عقار نيفاناك على كلوريد البنزالكونيوم</strong></p><p dir="RTL">يمكن أن تغير المادة الحافظة في عقار نيفاناك وهي كلوريد البنزالكونيوم لون العدسات اللينة، وقد تُسبب تهيجًا بالعين وآثارًا جانبية بالقرنية (مشاكل بسطح العين). إذا أخبرك الطبيب أنه بإمكانك معاودة استخدام العدسات اللاصقة، يُرجى ملاحظة أنه يجب عليك نزعها قبل استخدام العقار والانتظار لمدة 15 دقيقة على الأقل قبل إعادة ارتدائها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم دائمًا هذا الدَّواء كما أخبرك الطبيب أو الصيدلي الخاص بك بالضبط. يُرجى مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدًا تمامًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم عقار نيفاناك إلا لعينيك. لا تقم بابتلاعها أو حقنها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجُرعة المُوصى بها هي</strong><strong>:</strong></p><p dir="RTL">قطرة واحدة في العين المصابة أو العينين المصابتين ثلاث مرات يوميًّا، صباحًا، وفي منتصف اليوم، ومساءً. استخدم العقار في نفس الوقت من كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى يجب عليك استخدام العقار؟ وكم المدة التي يجب عليك استخدامه خلالها؟ </strong></p><p dir="RTL">ابدأ قبل جراحة إعتام عدسة العين (المياه البيضاء) بيوم واحد. واصل تلقي العقار يوم الخضوع للجراحة. ثم استمر في استخدام العقار طالما يخبرك طبيبك بذلك. قد تصل هذه المدة إلى 3 أسابيع (لمنع وتخفيف آلام العين والتهابها) أو قد تمتد إلى 60 يومًا (لمنع تكوُّن وذمة بقعية) بعد الجراحة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيفية الاستخدام</strong></p><p dir="RTL">اغسل يديك قبل البدء.</p><p dir="RTL">&nbsp;</p><table border="1" align="right" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center; width:249px"><img alt="" width="120" height="116" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAALsAAAC0CAYAAADMxl2/AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAB3RJTUUH5AYQDTcG7+THWQAAIABJREFUeJzsfWd3XNeR7e6ccze6GzmSoAhKoiTKQTOyZz7Nzx57jccztjSyKIkkCJDIDaBzzuF9gHeh+vACjLJB6tVaWCTBDufeW6dO1a5dVbZ8Pj9pNptot9uw2+1wuVyw2WwYj8fo9/vodrvw+XyIx+NwOp1ot9vo9/uYTCaYTCYYDAYYj8dwOBxwuVzwer1wuVwYjUbodrvo9Xro9/twOBwIBAKw2+3o9XoAAK/XC6fTiX6/j36/j+FwiPF4DKfTCZfLBbvdDi2TyQTj8Rij0QjD4RA2mw2BQAAulwuNRgPtdhs+nw/BYBCTyQT9fh/j8Rjj8VjeCwAOhwOTyQTD4RCTyWRqzVzDZDKB3W6Hw+HAeDzGYDCA3W6H2+2G3W6X99rtdthsNrkfk8lE1mqz2WCz2eQ1FH6+vh5+lvnD9+nPBSC/53f3+32MRiM4nc6p6xuNRhiNRnItvKf8HP7eZrNhNBphPB5PrVn/6PXztfpemdf5usJr4TNwuVzyXPr9vjw7rhmA3DteQ6/Xw2g0gsfjQSAQQCgUQigUgsPhgDOfz+P8/ByVSgV2ux0ej+cFJfN4PGg2m7DZbOh0OhgMBvJF/X5fFIHK7vF4MBqN0Ol05P89Hg8ikQgcDgc6nQ5Go5EodKfTQa/Xk0V7PB54vd6ph8gH6fV6AQCdTgfj8RiRSAROpxP5fB6VSgWhUAixWAx2u33qgQyHQ1k3v5fKTwUZDocYDoeiBPrBTSYTWQfX6XQ64Xa7Rbn4XXy9+X69Fn4WX2+z2eBwOKZ+9HOgUmnF0EqoFcTpdGI0GqHX62EwGIiyu93uKaWmkQoEAnC73XL9VHZes6nQfPZUet5TKqBe5+sour7P2ujxWvSz4ndxbTRKrVYLw+EQoVAIqVQKwIVRdTgccB4dHWF/fx/n5+eigDabDU6nEz6fD36/H+PxGM1mUxTP5XIhFArB6/XKQtrtNrrdrjxkbSVcLhfC4TCSySRcLhd4kvR6PfkZjUZwu93wer0IBoPw+/3o9/uo1+totVrodDrw+/2YnZ2F1+tFq9XCeDxGOByGzWbD0dERzs/P4ff7kUgk4Pf7px4ulV0rKq91MBjICQVA/p83nkpdq9VweHiI4XCIbDaLWCwGp9MpD8nKuvOB0DDwtOz1euh2u7DZbIhGowiFQi9YU24QKiF/9IaiAoRCIQSDQXmww+EQ3W5XTiBew3A4lPvZ6/Vgt9sRi8UQCARk7R6PBy6XC91uF41GA7VaDfV6HQDg9/vh9/sRDAbhdrvlHnFdvHdvI6ZBGQ6H6Pf7okvaEOiNOBwOUavV0O/3kUwmxaPw+/0XXkQ+n8fx8TFyuRzG47G4Fm63G6FQCKPRCK1WC4eHh2i323C73QiHw8hms3LDu90uSqUSisUiOp2OWAe32y1uBQC43W64XC60Wi3UajUUi0XU63VRKL/fj3A4LMrRbrdRLBZRLBbFajscDsTjcXS7XYzHY7HQhUIBuVwOLpcL9Xod8Xgc8XgcLpdrSmG4GanoNptNNh83Oa0j30frUigU8NNPP2E4HMLtdiMQCMhG1cpnKrp2CTudDlqtFtrtNprNpigmHxjXR0XnRqSVpqXWbpDX68Xs7CzcbresezAYiBunT4jhcCgKzO/n55ivq9frOD8/x/n5OQqFgmyMZDI5pdR8Vv1+Hy6XCx6P540VXRsLniQ0VDabDcPhUFwW854PBgPUajU59WmU4/E4EokEnHyTy+VCNBrF7OwsgsEgPB6P7PBarQa73Y7BYIBoNIpEIoF0Oo1AIIB+v49qtSp+b6/Xg9PpRCAQEIvh9Xrh9XrF351MJmg0Gjg6OkK5XBbFCQaDCIfDiEajCAaDaLfbODs7w/HxMQ4PDxEIBDA3N4fZ2Vm5ER6PRyyU2+3GaDSS1y0vL8vJpP1LAOIuTSYTsXQOh0MURluO4XAoLlkikYDD4cDdu3dx+/ZtsTparHxcKiyVvN1uo91ui3/p8XjEYml3gevW7gTdDJ4EXq8X8Xgc4XAYHo9HfFeeHG63W354TyuVCprNJtxuNxYWFjAzMyOu32AwQLvdBgA0m03E43H4/X6EQiHMzc0hnU7L6UnLzk2vN8GbuDNW95Frstvt8mxMF5HXXCqV5Nrq9Trq9bq4pk6fzwefz4dIJIKNjQ18+umnSCQScLlcGA6HaDabqNVqSKVScDqdyGQySCQSCIfDcDgcqNfrKBaL8Pl8iEajsNlsCAaDSCaTyGQyEpQOh0O0220JCDudDiKRCMrlMiKRCOLxOILBIAKBgCh7p9NBPp/Hs2fPJBBdWVnB0tISotEofD4f7HY7Wq0WwuEwEokE6vU6HA4HVlZWcPfuXUQikSm3QD8Ebrxer4fhcCgnGm8k/cJyuYzDw0O0Wi2sra0hHA7jV7/6FTY3N+Vk0wGpVkZ+H92YbreLdrstm6fT6aDRaKDb7UqQ73Q6xTfVSk1flevkaxnI6eCUys44h8ao2Wzi+PgY5XIZrVYLPp8P6+vrclJ3Oh2USiWcnp6K2xWLxRAMBpHJZLC6uopkMgm/3y+niL72t1VwregUuklUdqsg2GazodvtolwuI5fL4fHjx8jlcmLlAcDpcrnkgYTDYSwsLCCZTGI0GiGfz6NcLqPb7SIcDiMWiyGTycDn86HX66FSqaBUKqFarUpQEAwGkUgkEI/HEY1GZdPwxmu0w+VyyevT6TR8Ph88Hg+CweCUO9FqtZDL5dDr9dDpdNDpdJBOp+W4ZFBaq9XQ7XbR7XblCNdH3lXi9/uv/f/hcIiDgwOcnp7C5XIhHo8jFArJTfb5fC99eE6nU66NQTtdDboAdKN0gKqRESo+N4UOZs1rZPzDE4xCAIIKxOAVABqNBvL5vPxUq1VMJhNEo1HMz89jdnYW2WwWgUBgSsnogv1cwhP3ZeLz+aZOZt4znjROHYh5PB7E43GxDtVqFc+fP4fNZsPm5iYikQh8Ph+GwyGOjo5wdHSEYrGIbrcr1jwejyOVSskRR+VkIDoYDDAcDgWSZCBMy81jiwvk8enz+UTpbTYb4vG4KNlkMpH4YDKZSDyQz+dht9sRCoXkZhEupd9L/10HVXQd+LtcLofvvvsOxWIR2WwWoVDI0oKZaImV0K1gHDCZTBCPx194vdX79efro/wqS8cNo5GhdruNSqWCQqGAWq0Gr9eLWCyG4XCI4+Nj7O3toVwuo9PpAAACgQAikQhmZ2eRSqVk49C1IIrG58f/M9GoVxHtoum4hS4cN7n5HfzpdDpoNptotVoCeHg8Hnn2To1QaPio0WjIm+haBAIBdLtdVKvVKavvdDoRiUSQSqUQjUbhdDqnlHs0GslDBiBHOCHGcDgMv9//woOhBAIBhMNhVKtVlEol2O12rK2tIZ1OA7jY+ZFIBL1eD8ViEeVyGb1eD7VaTZAd3kwiRMwlWAm/fzAYoNvtolgsolqtYjweY2ZmRhChqx6YiYXz71o5+VDflXCDautvhfF3u13UajUUCgUxBna7HfF4fCoQDQaDiEQiSCaTyGazSCQSCAaDoh/aajIm0XmHN8Hbr3oP79N1bpJ5rVybjr+cDGK8Xq8kfAaDAU5OTtBsNhGJRJBIJMSPPzk5wenpKYrFIgaDgbgQc3NzmJmZEd+JAQKhrEAggEAgAKfTKb9nMBqJRER59LFKcblciEQicLvdKJVK6PV6otAMyMLhMJxOp6A3tPDchPxsbmyiIFR+qxtXq9VwdnaGYrEIu92ORCIhMQMRJivREKSp4FZJGroT5kM3N4vV5/D7GHfQmtGya2HcVK/XUSgUcHJygn6/j2aziWg0Kn7x7OwslpeX5ZnSEGljRECAJxQNGOOD15WrDAS9DHMTaR3h77QLaLqCAOAcDoeCghC/LhaLeP78OQAgk8lIcNrpdKYgq2g0KrBOLBaDy+WSgIsuisvlkkCSGOh4PIbf75f3BwIBuSjzgvlvv98Ph8OBcrmMarWKk5MTzM7OijvD1wQCAXg8HrTbbQl+Ce0xKtdZOFNpdPKkVqthd3cXhUIBwWAQ2WwWs7OzSCQS1/qQL3NB9PH7NqJhSn6v+Zk6mWXmSRKJBEajkbifRLcymYygLuFw+IXP48bU1p1JnTe9puvumdVpr0EG/RkaFNAoHAA4J5OJHFGBQAC1Wg37+/t48uQJFhYW8PnnnyMWi6Fer6NcLqPZbMJut2NmZkasZjAYlGRFpVJBo9FAIBAQGNPlciGfz+Pp06dot9vIZDJyg4nqmP4acAnZESkBgEqlgk6ng/39faTTadn99CW5o4lpx2Ixecg6CNTpcyoMLSwtU7lcxpMnT9BoNDAzM4OVlRUkk0nJ7vIUMq2uqdhWCSf9Ho3cvEwBzAeu4wsqHYX+Lu9hv9+H3W4X33tlZQVerxfz8/NIJpNTwSY/j3Ci+Zk6l+JwOF6Alt9GtPExN5b25a0UnveY181rB/4eoHLx1WoV/X5fcHX66i6XC5VKBeVyWVyGaDSKaDSKcDg8ZdG73S4ASMBI7guPOZvNJq6P9gFNazcajeS4LRQKOD8/x/HxsQS7p6enODw8RDQaRSwWe+FG6USSuYmucg/G47EgPq1WC2dnZ5K5XVxcxOLi4hQKY7oq5mfqz33Zw31Ti2hyWXgv+Sf/rpXe4XAgHA7Lc0in0y+cVPTBdVbZvDarBJD+/p9TXvYdekNIptnn8+H4+Bi1Wg0+nw+JRAKBQABbW1tYWFgAAJRKJRwdHaHb7UqwopNIzWYTxWIRtVoNbrdbEg79fh+lUglnZ2fo9/tIpVKIRCLIZrMSyHJh5uJHoxFyuRy+/fZbbG9vY39/X4LEYDCIUqmEvb09LC0tvfAAGLm73W74/X6B25jeNn1Zit1uR7/fx7Nnz/Ds2TPU63Wk02lks1ncuXMHmUxmCsZ7VeLTy5T5bY5+Uwlp6flvnQ1m5rZcLsPlciGbzSKZTFqm94nSmevjycjvfZMT6XWvz0qxrwIzzPe/AD1Wq1UcHR0hGo3C7/cjk8lgaWkJkUgErVZLoCgdpTPAY0aw2WxiMBgId8Jms0nCqVgsynGZTqcl7Q+8SHAiD+f09BQ//fQTvvvuOzx79gzlchk+nw9ra2sIhUKo1+uoVCqoVCqo1+tCPiMKRBzf5XJNPTRCjxqRoTXv9XqoVqs4PDzE/v4+QqEQ1tfXsby8jNnZWcGXr/ORr7rpP5dY+bLa2nKN9Kl5yhI4IHzL4FQjH1brfhexxquKdgvN0/FlSq5/BI0ZjUao1WoolUpIJpOSPGDyo1KpoN1uIxaLCTFMWxGiLgAED59MJmLt+/0+wuGw4O/hcFiSGr1eD+PxGD6fT5S/1+vh8ePH+J//+R/8+OOP2N/fh91ux+3bt7GxsYFPPvkEdrsd3377LarVKs7OzvDs2TN0u1243W5R/sFgAJ/PJ9wet9strk2j0RDuRLfbxcHBAXK5nBCnGo0G/H4/5ubmsLq6Kok0ABLsmqzEmyJXIT4mQmSeSm9Lz30fxEneR6fTQSAQwPz8PFKpFOx2O8rlssBujMypNOSrdzoddLtd4bYQY6/X66jVavB4PJiZmUEqlRJmHxNKxN8ZhDCV/d133+FPf/oTjo+PMZlMsLy8jPv37+P+/fvY2toSC7yzs4NarYbnz5+j3+8jFAqhWq0KHXQymaDdbuP8/FxOpsFgIKeQx+NBq9XCo0ePcHBwAJvtguoQDAYxMzODpaUlZLNZRCIRAJdxwM+dMXxbsVJ2TcfVFFnzPe+LvElc4NRwWygUwszMDMLhMOr1urgEgUBA0v9MtLRaLbRaLaFR0up3Oh2xroQY0+m0ZGbJvRgOh0IwImvxhx9+wDfffCOui8fjwdraGj755BN8+umn2NjYkOTR+vo6xuMxcrkc9vf3hbDUaDTESvV6PeRyORSLxakCBfLpHQ4HBoMBcrkcWq2WkMcymQxmZmaQTCYFT2cQr6mmN1GuUlqdidRwoX7fhy5O+rbMUjI5w+QSqbd0URjVM9ix2WzCabHZbMKBHg6HgqVHo1G43W7J3pXLZUwmEymyKJfL2NnZwR//+Ef84Q9/QD6fh9vtxsrKCj777DPcv38ft27dwszMDIALy7SwsIDxeIxyuYzT01OhgXo8HsRiMVFskoPIV9dVS/pavF4v0uk0bt26hfn5eVkbMM08NMlkN02uwqutOOc3+XT6OcQJALFYTJJEk8lE+OaTyQQzMzOCnFAxWq2WUC5Z5UIuDRWdlSKJRAJ2u10sOk8MQpLlchkPHz7Ef/3Xf+E///M/8fDhQ6RSKXz66ad48OABfv3rX2NtbU3gRVb4RKNRQXjK5bIwAefm5pDNZuU7SQwjOYxrHg6HKBQKgtv7/X7Mz88jk8lIXAFcBtC05hpeM7nV/0y5KiEHXLpfZgnlL07ZbTabJHeCwaBAiY1GAz6fD5lMBsFgEOPxGO12G7VaDa1WC8AFy4w4O1EXUlXj8TgWFxfhdrsl88riDiID5B7/+c9/xh/+8Af8+OOPaDQauHfvHn7zm9/gt7/9Le7evSvcFhKP7Ha7VCTNzc0JjTMajWJ1dRW3bt2C3W5Hs9kUa0wuudPpRDKZxHA4xLNnz5DL5VCv1+FyuZBOp6XMj745XTwqtS4GYcxxFZT5jxYrheemJMOS7tsvUtmpOHxoLJez2WxC0mJBM8uzaFlZmsXyuXK5DI/HI/SBQCCATqeDs7MzQUiI03Y6HTx9+hTb29v485//jP39fYTDYWxubuLrr7/GgwcPsL6+LoquayapXD6fD4uLi+Jeeb1ezMzMTP0/kROiM7yuyWSChYUF+Hw+nJycCMtvMBhMkag0L4NyE5XkKgKatupa2X+RbgxTvoQDWWBBngmJPlT2brc75eMzWKXFZ4VSMBgEYU2S6FkBNR6PUSwW8ac//Ql/+ctfcHR0BJvNhvv37+P3v/89fvOb3+Djjz+W4JD4MABJT1Pm5uaQyWSmCn/5HmLHtMj01Ul+i8VicLvdqNfrUkPbarWEI3IVHMcN8CY01p9Lrsrm8j6wEINUbtKpf0nitNlskhomSYvICglVZDHSemqGZK1WQ7VaBXCBs/OU4ObQUCCris7OzvDkyRP89NNPyOVy8Hg8WFpawpdffomvvvoKt2/fFkUnFk9XgorOdh5USs1z7nQ6clJpshdhUyo9kSWWlHFTWJV+aY4G/3wf4DrTspNHQwNHuUkb9+cSp81mk0COvWFIp2W6v9VqCW89Go3C4/FIQW6xWESz2RQUhCV3pVIJtVptqgWGzWZDqVTCX/7yF3z//fc4PDyE2+3G5uYmvvzyS3z99df45JNPJFPJ+MHhcAiGD1w8QMKHAKZS+MwZsGBcP1CdIWRwzIocIk9kTWrhxtCfcRV56yYJNzWVndegW4BQaFA+ZIV3ApeBn4YR6b9riJFlZQ6HA8ViURSavPZIJILBYDCVyvd4PEgmkwCAer2Ok5MTbG9v4/j4GIFAAIuLi/jyyy/x61//Gpubm1MlX5p7rtER+v5WgaFOEfM9fMj6c7Siah9Ww5J8+JprclMtuhXJTSs7A2oGp9qyW/HvP0RxanaYrv8k54UtK1iYzbK8RqMhBRS8ecxIsrKHpwEJVsfHx3j+/DlOTk4wHA7x0Ucf4auvvsKDBw+k7I/C4zYYDIrikscyHo/h8Xik+FY/JBZM061hhpj/p/uOsHUHq7KYiNJlYPzRPu5NVIirYguzOwEJciaMelPzBu9SnJPJRNwMv98vylwqldBut+VBa7put9sVP58tGgaDAarVKur1+hRpjNAjWYpnZ2fw+XxIJpO4f/8+vvjiC2xubiIajQKYJoaZ/UHMulGTqM//07xqEoisuCL09ZlNpBU3LZwmE91UC3jVRjSLGHgi6s37S1B04O/K7vV6pbDW4/Egn8/j6OgIDocD6XRaqoSGw6Fg5QCmaLq1Wg1HR0dyVCaTSUQiEbTbbZycnGB3dxePHj1Cp9PBnTt3sLm5id/85je4deuWVMOQkch0tiaccXOZHaEo7BXJU4bHNwCplNIsOt2+Tbe1IxVYf4dehyoEuHE++1XEL/1v4NKds9oYH7I4aZ0JR+nkEZVEw3kMAAnP0bUg+5FFG/T9WZx9fn6OZrOJUCiEjz/+GF988QVu3bqFRCIhi2EiB7D2PWmVrlIyk3qrrbf5Om3x9EPmd2iOt94cN9GqW4m+B/TXeQ9pEMzT6324rrcRpy5P6/f7aDQaEqySHgtAsp66BK7b7QqaYbfbEQ6HEQgExBU6OTlBLpfD+fm5pPaXlpbw2WefTeHowGUwqh+SPpqpsFdxrHUfFf7uuoY6JkqjA1TTwmmcXzcvuunCZ0a6BE9dNp/VRuR9uJ63FTsVi1Xm1WpVcGoAU8kIrZD9fl+SSaxLjUQiQgPudDrI5XI4OTlBpVKBw+HA0tIS7t69K+xFVqFoi6wVSfvHWpGtjlszBf6yU0B/BwPgqyybjgneF0WnkAyns9c0Vhpp+sVYdiZW2Mau3W5jMBjIcafbULMP4Pn5ORqNBgAgmUxOdaIl85F8GRYsf/TRR9ja2nqhYv2fJbRo5sM2N5MJZZqvuQlKYhWIM9ZhMsl0X7Q/fxOu4ecWSSpVq1X4fD7p3AtctlBjXz/SflmF1G63MTs7i0wmIxX59N+r1aqcEnb7RROe9fV1rK6uvlFfkZ9LNC6vxXSj6MNrRblJRRx6PVwjaQIariUVW7/nlyJOBqSVSgWBQEBK2IjQsM85mYNU4n6/D7fbLQ1MWcLH1mqlUkkymbFYDAsLC0KfBW5W5K8zolbHuU5gaTSHG+ImWEWNvvCHbQbJCuXzvM4d/JDFToSl2Wy+0NeaBRuEHUnVbbVa0uI6mUwKH77ZbKJQKODs7EyaYsZiMaytrWF1dVWw9Jsi2n0xFd58ndkqQvvx/2wxC0p05pR5EZL72N2Lr7sJ6/9HiVN3cyU3hF22GGyydbVOGLGulFlPNkjSvRZ9Ph/m5uawtbUlDXlukujAWKNSr2Kpb5KSWCWUmEOgG8OTmt3XgJt1Df8IcbJUi+lz3YWXwQz7AzabTTkO2RaD85bo3rAjGC3/4uIi7ty5g5mZGQmWbhqioS336yj8TRJT4U0CGJmstOy6NcUvRemdAAR7DQaDiMVi0rcRuGQRttttqQYKBoPS9o6oC4NRduBiJVEymZS5R8Tub5qiW/1oMZEXbo6bpCS60ITuiT61WRRPeraZYf0liJNsRr/fj0gkgkgkMsUlZ4BDKDIejyMWiyEej2MyueiUe3p6ikqlIjWZHCXJMjcT6ropVtNU7qsU3Uy1W733ny3mWnTpIPMDnJcFXPLzf0niJLeZu54JB07LoLXm61hy53a7ZRYRG8Az86rrQxOJhDyEq9COf5aYjU2tqK5MvDD5wv+7aZVKWmjV9VhIs1eMucl/CSLKrjvlMiDloCv2V6SbEwgEpMqHCSkWgNhsF41P0+k05ufnEY/H5TNvki9ssv+oIJoKq8VsIHrTLLsWwo66m4AZJ1kl0m7itbxLsetdTyvGfoDsvMsGShwzQ6umR41Q2enqMKvKCqWblpYmn0YPAKaC6P4wFNO/vQnXcJXohk50YUyekN64vxSxA3ghoCFcpZvXs9kRyUV8Dy08a1XZ7i4ej0sb5Jui4Fo0T4TKzo2r2Zf69foaTGz7poiGHHXNqVWnXtOy37RredfiNCtZGLjw3zwGOYkMuDzSgQu0hrDkZDKRWZmc5ABYFxTcFKG7Yjavt0JgrPgzN2kTM5lEo6XdGCsE7Cou0Icqdo3FssLexJtN7gg54jabDbVaTUhhNpsNyWQSy8vLSCQSgqvTP75JikGhi8V7oMe669dYWfabqCRa2WmwKFbrvUmu5c8tdo0umPirw3E5910rO60gezfWajUAkOlqiURCmtmbLSjelbxM0Ux05TohFwjA1KxVVkeZgam2oO9C4d9k41x1bdodZdUXn+EvXZwAJFvKTlmcjuzxeGSStMPhELSCzYQ48LfX603NHKJi60EAJpz3NqIftBVbUfeGMbkvVsJJgBpCbbfbiEQiwvvR6AzRDmae3zZJxvVe9VmmS2XycjSnR7cKYc96Dnmz8tv153/o1t3JiXa8WeYE6lAoJFOq6ep0u13hwbAom1VIsVhMFJvW3SzQeFvRuDgVDpjeBBobt0oaaTydHCC2AeGgBBaNW7XseFcZSL1ejeObUKD5b10iqA2Kbog0GAwQCARk2BvBBatn8EuAHp0ej0ceMtvbceI0R6nrUjT66q1WC41GAw6HQ4ZQkUJA0Ur2rhWeCIougjbjDf19VATg8sGaRdWmC0CUyWazTRU96PpbUiDM633Va9TWmN/N7+C1mJ+lDYnup6Ob0nKQm8fjQSgUQjAYlE1lxmdmr/YPVZxut1t46pxfyhYY7NVINiRbVLBTWKlUkk4CqVRqaiYp8OLxqI/rd2XhNYJ0XbJHt5MAMLUpuC5CkUw2sccl2/7pfiv6vbpK6E1cGt4PrewvC+j1NWqaNptasViD7VH4HgDSNAnAL0bRgb93F2DAaVbwM7mkH36/30cul8Pu7i729vak3UYikRD//h9xHF61cYj9U7Ri0hqaCRW6KzbbxdhKblLSJRqNBiaTi5YjkUhEYhzW0Jqb7Lrr1y4Wv4fF3jrxw3Wb1wtcKq0ukyyVSmg0GkLrCIfDAgWb69EKTteVFO8PWfGdVHLebLoptDLEnNmXpVQq4dmzZ3j8+DFyuZxM1SON4B9xs3SAZrbG02s2IVRzbWYROfnewEXLvPPzc+khz3E7zCEw72D2j3nZRtdIjnYlrPgrFP16HStQ0Qn/tlotxONxcVuIpunNZbpk7D5w03rN/xzi1N272FJ6MplMMR1ttotuAtVqFc+fP8eTJ0+wu7uLer2OhYUFaaFBWrBVWv1dY7ma0gpcKoS29qa15NqINnEmFNfHU67f76PdbiOXy+Ho6AitVkvcNW7Jm1zdAAAgAElEQVRoli/q3phUFisuil43FVsHyTrQpuie6npt/DczvmxByC7KtO66W+9Vz4H+/7tAlW66ODmNghOP6auzey4b+nc6HRQKBezs7ODJkyc4Pj4GcAEvkjNDuSoQfVfQo9XG0ZbyqofHkfP1eh3ValWOfp4GxNhZlcVaWqfTiVQqJT0w2RfH4XCIgukAni31+KfV9eq1MWBk7xu9VmamXS6XtDthP0reZ4IEbHSle+hY1daaKNJ1PXk+JHEClwESrQWPPU6IZnvnUqmEk5MTnJ2dYTAYIBKJCIarlR2YDkoZwL3LLKpV/adJeOImrdfraDQaqNfrQm1gpzLmCWjNqWDNZhO1Wg2dTkcmegOQbgs8+Vi7q90QclHoA/O6rYwAXcTJ5KKxLIvbqdjNZhMulwvBYBDtdhuFQgH1el1a/ZGzFIlEEAgEZBNxPeY4GX0Cviz/8KGJkzeDBdUMckj29/v90hmsVCohn8/LUNzZ2VnMzs4ilUrB5/NN9fjWQRQpA+8KheGRrlEYs2UdcFEXe3p6ir29PRwfH+P8/Bz1el0USSt7r9eT4Wicdk1+/mQywcbGhpQtJpNJgfjY6VhfnxUNWCu7eS2MG+gSaeZpr9dDMBiE3+9Ht9vF2dkZ8vk8er0eQqGQ1CBwDq0VjZdCRdctvK0w/Q9VnH6/H5PJxUTqSqWCarWKWCw2NZadEzYqlYoMGEgkElNDcWmRrJIWOmHyrkRbSe0DU2krlQry+TwODg7w7NkzHB8fI5/Py2wnPQyNwTe5+eY6SXNm6SITNLSKzBTrfIKJuphZT+1KmLkBDaeywzLzIaenpxIvEWlhT59wOCxQI6nY+hlQtPUnGPEujdFNFWcwGMRgMECxWJRZoDwaOUWjWq1K1wBy1ufn57G+vi7T9Dg60iqF/3NUKPEzddPSdruN09NTHBwcYH9/Xyz66empDE7gFBFSeTXCwQdulqyx8avX6xUUJhwOC51CM0R54jAO0IMAdHGIRkd4KmmIlPfL4XAgEokgFArh6OgIp6enePToEU5PT+Hz+dDtdlGv1xGLxRCJRJDJZORHDyzW32X21GQTJfr7H6o4HQ6HHOvsL0JffTKZSEE1j/zRaIRgMIi5uTmhB+huWVZB6btmPOoMIv1bwm+7u7vY3t4WRS+Xy+Ke0B9ns1aKhiZprWkJ2SUtEAjA6/WKMmhMWltxKrZWcs1A1D9WmVyuR/v9TPIBkG5suVwOdrtdgmXWD5+dnSGbzQpS5vV6Jf4id5/Cdf9SxEkYrt/vCyoTDAaFGMUbe3p6KtnUeDwu/jpxXJ0E0T6gVvR3HQjRxTo/PxeU6PHjx9jd3UWpVBJfmtAgNwiVndO79Rq1AvB+sEOCVcJMuylacfVmtBL9e94XPYGasRQ/i9erwYR2u43j42NR9lAohN3dXYRCIWxsbODOnTvIZDKIRqMvgAg6H2EVyH6I4mSLamLt8XgcgUAA4/FYfN9CoYB8Pi+DwhKJBLLZLNLp9AuBqfZZaek1UQt4NxAXR92cn59jb28PP/zwA3766SeZ7tHtdmG328UiUjjWcjwey/h6UmAJ2el1er1ezM/Py0j6q0Rvbv2718kz0M2xGnTAuCcYDCKZTApEyk5s3W4XxWIRw+EQbrdbkCS2HeT9oJ+vY6irklk3WV4nBpRMNSN7v9+PmZkZZLNZ+P1+tFotVKtVCUw5NS+VSiGVSiGTySCVSskAA50UMemnVCA9re1trcjh4SF2d3exs7OD3d1d7O7u4vj4WNptk65MhibjCU78CwQCCIVCiMfjyGazyGazU+xAbqZGoyGzXTVlmTfcJJyZD4Q3+1U2uHkSMGjWgf/MzAxu376NbDYrdORms4nz83Ppwcn6A7vdjvPzc0SjUayvr6Pb7WJxcRGJRELQNqtk1k2X6xCk6+6zs9frwel0IhQKIRaLIRqNinugp941Gg2Mx2PEYjFks1nEYjE5FjUXRSMP+sv178wdaf77ZYrBIO3777/H9vY29vf3pVrK5/MJBMdEUbvdxnA4FAbgwsIC0uk0QqEQkskklpaWsLCwIK0/2G2hXC7j/PxcRtTzWnUnhlfhwlhdo3m9OrilK0TYlpnUyWSCubk5eL1egYrr9TrOzs4wHA6FtcoNr0+vXq8nJ5PD4UA8Hhe3S2+m192gP5dc9/3aKJiv0Z6F+RrnzMyMcCPMahb2YS8UCgJtLS0tYWlpCW63G+12W/xhM21vBl6ad3Fd9pMWycrakK7w9OlTPHz4ELu7uzg/P0etVsNkctm4k3EEg20GeKlUCgsLC7h16xaWlpaQTqelMasZhNrtF8MVUqkU8vk8Tk9PpYMCZ6ZaiUnyMnF3rfyaganvHV0ZKich4clkgrW1NaysrEz1cTw7OxMaw5MnT1AsFnF6eoput4t0Og2n04lSqYTt7W3ZOLx+p9MpuD4zvlyHzr5aXSevz3Qp3naTmOiR6QqTpkygwiyssQIAAMAZDocRjUYxGAxk8Barkjjmkd2+/H4/5ubmMD8/D1KD9UPhl12VndP+sMal9Qaxulmabfm3v/0NDx8+xM7ODs7OzgQXZ5MnJmAATBUxhMNhzM3NYXl5GRsbG1heXsbs7OwUmkTERDeOikajmEwmsuGZZSWn3RSrDKW2UjqusWJumkrjdDrFajscDiwsLAg3nRBpsVgULoxG1jiHNpVKoV6v4+joaIqrP5lMkEqlpq5bKwxgDSpcZVnf1WnAazPjH702DSLo9+lknH4OwN8DVB7LtGjkxjBDyDYZwMXI9mg0Cr/fbxnBayW3unD9kDSHRcN+mh/CpqocLcnkUKFQQKVSkTQ7Z5qm02nxvUlOczgcCAQCgkrMzMxI4kwzPamoJlRKjJ2YNnBx6jGBQ0XTlsjKspv3SP/bZrPJ5+iBbfV6HeVyGZVKBV6vF4PBAA6HYwpG9Hg88Pl8mJmZkc3+6NEjARUqlYpw8dk3n3Dy6uoq1tbWpga5mXDxVajSVTHKuxCr7C9/r3VEv4b1B6VSCfV6XXIpsjFYsKHpubQK1WpV/F1aMgZ2rGQyo/jrlN3MDvK9ZicDSrfbFT7O/v4+Dg8PkcvlUKvVZBQO10Q4lG7W7OwsZmZmEA6HpfCCuLVmcnIT64nP5rq5WRi0djodiQ3oAml37lWQDX286u/Rv2s2myiXy/IcAIjFotUHIL305+bmZC6tx+PB3/72N3S7XTSbTckXVKtVHB8f4+DgAEdHRygWiwiHw1PKbp7IVjHYz6no5nPQJ78Jx+p1sqjo5ORECoumlN3lck0RkJgxLRQKKBQKqNVqsNlsyGQyWFxcRCqVkrrUqy76urSz/n/zosz39Ho9VCoVHB0d4fHjx9jb2xOOOUsCU6kUlpeXxZdlK212G6YPfpVvp90n8+ZR3G43IpGIzJ0i4kE4j6chZxa9bhaSfJXJZDIVVDMJxiknwWAQgUBApntb3dvV1VWJVbxeL/b396UDBDc5B75Vq1WMx2MZE0SOkxXsaRWH6Xv5roNZM1g2YwhTx5gAPTo6ws7ODjqdDuLxuCT0gL/TBZhYIK20XC4jn8+jWCyi2WzC6/VifX0dm5ub0pP9VRZpJbR85uvM9/T7fUEa9vf38eTJE+zt7aFSqUiP90QigbW1Ndy7dw8ff/wxbt26hWQyKZweJk14s6zch1fhg5AewJwEj0jgggXpcDgE7WDsoE8K/UDM62W6nq0GeZqVy2VMJhNxFemCMbmlP5Pu3mAwQCwWw+effy7r+Otf/4qHDx+KK8iCeSq9zWaTiSj37t3D0tLSC0CFvn8mq5Q/PyevxirTa7o4zKIfHh5iZ2dHSkmnKsICgYDcqHa7jUajgVqthmq1ilarJaSvu3fv4u7du4jFYi8sxNzZV8FXVHD6tFbt2ZjhZEXUo0eP8OOPP2J7extnZ2eYTCYIh8NYXFyULOHm5ibW19cxOzs7pQjad9ZHs4bazIekiWz8UxdG8MHTgtPN48nB3+s+ktcpAj+P1rzRaODs7ExmXHEOFWMOU9E1kqX73ywtLaHRaEjjp6OjI+HxkwzHvIHP5xP4ORqNCrntVZRXox7vStnNxCR/d5Xw/jUaDRQKBZyeniISibzAcXLy5mkeNwNTwlHpdBr37t3DnTt3EAqFXrhQfbFWu56/M1l4hPHo/wMXFr1YLGJnZwcPHz7EN998g0ePHmF/fx+9Xk988y+//BKffvoplpeXkc1mkUwmpyySbqVhBltEH0xlNwuyKXb7RaMhrtPj8Uj5G/1qM4egue3ajTLXQSUFINb37OwM9XpdNm8qlZKyR/O04LXo3usAEAgEsLa2Jom0RCKB3d1dDAYDVKtVufelUgm7u7twOp2Yn58XPo0ZP5inoqkD7zIxpe8NxYzptKXXs6Oow3THtJFzMjmhUZd2uy0tJNhnfXZ2VtpPc0FWUbrpR1n9nqKVC7h4cPV6HQcHB/j+++/xf//3f/jxxx+Ry+UwHA6RSCSwubmJTz/9FA8ePMDdu3eRSCQEgTCV9nXiB/N9ev3awlPZOaHE6/VKVwbdW8csLrGyVHygVqgWKcWhUEj4SpoCzFOLm5nIFslodPMACPzITPHOzg7Oz8/R6XQwmUykKKRcLkslFBtjmffJfL4aQn1XYpUUsvLRtfvEoNXv98spzOclys4KHlbc6BbUHo8HyWQSi4uLMiiMYiZOzJ1v+nN8HYUPifECcAHn5fN5PHnyBP/7v/+L77//HoeHhxiNRkin07hz5w6+/vprfPHFF/joo4+QzWZfiMrJMtRwpha9VqvTiHkGKg4DI36H0+mEz+dDLBbD7Oys4LpM8Gj6sLbyOlbhd/Gz2dab95UzkJLJJOLx+NRG1rQHuhu8LgIMDGi9Xi9mZ2eRSCSwvr6OTz/9VHhEz549w9nZmcCak8nkyn6XL4OS36Wim5/NazMTc/r/CMUyl7K6uipwtC51dGpeNx8c3RiPx4Pl5WUsLi5KooaLsPLFr1qsTiBpf1i3kBiNRjg/P8fjx4/x8OFD/PTTT8jlcphMJshkMvj444/x+eef41e/+hU++ugjZDIZS0TCtKa6VlMrt9V6rf5PY+/cuDoQJcedCSz+aAt/3eebySkiM2zb4fP5Xihkvyo+4gajcvAhM6tMzns4HMbCwgJyuRzy+TzOz8/hdDqRTCYtwQOu00repa9ufqbWletOaCp7JBLB8vKydIPg6SSWndaFhdaNRgPlchm1Wg3z8/NYXV3F0tLS1AOxggqvUp6rdr3NZpNOBjbbBRfn2bNn+O///m/89a9/xf7+PiaTCZaXl/HJJ5/gX//1X/Hpp59iY2MDyWTyhcykvnD+ny6YAF6syzTjChNa08c00R2rU0wHp7qIQxdvmOlr80d3EGD+gPRjvcarODn8HkLJeooK0RcOivD7/VhZWRFIslwuT9GEefybz8vqOVu5N28rpnJbxQv6O3nykPA2Ho9xdnY2dUoDgJOW1W63o9Vq4fz8XOgBLNJIp9MvYMcvuzgrK0bl1wXYwEVQenp6isePH+O7777D8+fP0e12MTs7i3v37uFXv/oVvvzyS2xsbAhaQN/UTIDwO61875cdt+YG0rAllZhr1pG+1Qbga3QRhw6YiUBx/YRTgctqfyv40grO1BQFsxZXu3V0bbxeL6LRKNLptExCJDJmZmf1NZrCa37XAaqVJTefiZULarfbkUgksLi4iOFwiGq1Om2UiAlPJhNJITM1HYvFkEgkplyY112wuViiMJPJBMFgEOPxGKenp/jhhx/w3Xff4cmTJ6jVaohGo7hz5w6++uorPHjwAKurqwiHw1OlfzabzbLwWm8A+rX6eDet1FV/cr36d7TerHU1Owho4e9IrtIPySpLSTSBySr9OqtTjPiyzkibr9HBr5mx5akeDoclMUZs/2WnNuWqrPPbCK8XuISCTUOpnyPh6kajAQBSn2DeDyetQK/XEy6Fw3HZv1E3KuUHW+GqVsjLVTdAB7eDwQC5XA5Pnz7FwcGBFBJvbm7is88+w2effYbbt28jkUjAbrcLxZbt57TFNNfxKtbGXKNVxK+vl+4e8xIcomuFCesN/yoUAjZuGg6HU9CZlTuoGZLmcW3eg6sgQ9433kvzvVYxwnX37l0KT2ddGMQ1md/b7/eFim6FxAldgBm1SqWCg4MDVCoVLC8vY35+Htls9oUUu/Z/9e+15brOj7PZbFN4ONvMHR4eSo+W9fV1/P73v8cXX3yBjY0NxGKxS79LBbVaEfRDMq3xdTfUSng95uew3QV9d7oNmrilffyr3Bu9Tr6GQTp70BCf10rIE20yuew1o10hnnRsWso1W7XMoFtjggf8uxnYv2yzWjE431Y0jGrlVjEoZ6Y9n8/LvWq32y+4r04GpcViEYVCQdq6scDBykfkm83jxrT45kXz/7X/X6vVcHZ2hkKhAJ/Phzt37uDBgwf43e9+h1u3bmFmZmYqSKNPan6HtsIv882vshJaUYHL4I6IicvlgtfrFd7KZDIRRqR+vz5qr1J0bSBcLtcUHVnPpKWS6dPQfK/po2u3zsq31cE438PTQbsL5nO+TonNU/BdyMueKeHSVquFfD6PXC4n/CTSOfg64O/KXigUcHR0hH6/LwUO8/PzMpFCfzEVT6eprXxhK0XXN2I8Hk8x8HiifPbZZ9ja2hLXxYpVqY/16/xtikkPpeigzmazveAidTodKYyYn58XekC9XsfJyYn4uS6XS5ATcoysFJ1jX7QvPxgMhJ5BghYZiizw1rAirad+LrR+pgW2UnTTxdJBpn6fWYv7MgV+lQ3xusJrMdExUwaDgfQJYtNZxmn62pzj8Ri1Wg3FYhE+nw/z8/NYXFxEOp1GOBwWq6ERFI1Q6CDqVfxS3pBut4uTkxM8f/5c6Ji3b9/Gv//7v2NxcXGq1bL5kPRn6d9Z3eirHpi2wtoF0M1c2dyUHQbsdrsQtXZ2dqRwxG63Y2ZmRtZsWjkqJDujeTwe2Gy2KT5HpVKRyi9Sdgn3mpU3dHP4oE1G4nWnsVXMZd6bV1FuU97kPS+Tq7Km5lonk4tkWqvVQjQaFV4S3U2Kk34h+5Mwa6eHD1hdGC2JyUYzF6YXrRWhVqthe3sb29vbcLvduHv3Lm7fvi2b7LoL1Ou4ympbfT9wiQaNx5dNgfg+tnKm1SR8xX45o9EIJycnODg4wNOnT9Fut4WCTHoxi0IIj+q1cr2s6SXMSxSBXRsymQzi8bisg3CgtlQ6gUS3zrR6VkbAvEf882Wgwj9SrgJBrosTWcBiUi+0XjiJvZJVR4KTqejal9NWxMwS6sVoN0crW6fTQT6fl2ZGS0tLuHfvHtbX16UrgA6UzM8w18OaTfPIJrSm38cgkGzLq/Bks+oll8tJTS5/2Ldld3cXGxsbuH37NlZXV5HNZsWyUFjqx2s/OTnB3t4eyuWy8FiY4WSHNS2mX84uXiSAWfm2ps9uZSWvMgr/TOFztcLadfxGZXc4HNKWkK4hIWrgcpPIHeQbEokEIpGIJcVT77ir0srm603p9Xo4Pj7G06dPsb+/j2q1ivv37+POnTuYnZ2d4onozWXCajqI1DOVdECnayu1/0crqWFXHoOtVgvj8RjtdhuPHz/Gzs4OGo2GlMQ1Go2p/pB0A/f29iTAHI/H4jsSLiUOnM/npQilWq0CAFKplARVp6enqFarU4zJYDAoFVf6Yev7YPWsrhN9ErwqevWPkpcBDfqaGb8EAoGpjtOcGKNf79SWmV1qQ6HQtdXz+ov0h5kLtpJGo4GnT5/i0aNHKBaL4u8uLS1NjXjRF32Vn64tO2MGDUdqVAK4hOF0wTJbU7M3TrlcFk7/s2fP8PTpUwwGA0mj05LQ72a5X6VSkRtMNCUSicDj8aDdbqNcLktnhO3tbVSrVfj9fqn8CofDaDabePr0qWwkVkil02ksLCxIoya6SKbr8iZ+tlasd5kF/blFW3kqu9frxdnZmbiFLJYXZddt0PTMoOu4CC8TfXxoYL/VauH4+BiPHj3C3t4efD4f5ubmpDETv8f8DNPS68/mpjRPGqujWwutKHtYkv1Jy12r1aQXOtmMhAO1n0zrwd45ZD2Ox5f97Z3Oi6mDGiXQww8ajQaq1epUphXAVK9IzmUl3ZfkrldJ61/ny2s05qZYdo0UAS+WBer1k3JNhmOlUsHx8bFY+qlKJUbzwOUYQauehqbyWP0/MK2QemHdbhe5XA47OztS+X7//n188cUXyGazUjWvP0MrFX9vBlW65tMMZsyNwHWNx2OUSiX8+OOP2NnZQbPZFB+PisgKJACSuOh0OoKS0DXSjY10zxmeNGRF6o4NlUoFwKX7dH5+LqdHMBicqopi3Su79iaTSaTTaSmuftlRr5+Hfo7635rReRPE3Hxk5GrjCVxeC1moDocD5XIZ+/v7SKVSSKfTUzGlkxfp8XgQDAalNZwVjGj6zlZ+lXYr9E1lMHd4eCjFvysrK9ja2kIikZhSGn6X/lOvgQqpA2X9/XqzcR2sr6UFz+Vy2N/fl24FrMqim6DZoFRS4CI1zRYahCJpMEajEUqlEk5PTxGLxRAOh8WQFAoFnJycyDAHTvtgfMDEEmsKxuOxdHIgF2cyueijTwXgwDC2z2acZXWime6heX9f5+T+R4jpuupknykul0t60rMDBP33qYJru/2yIobt7/QwMHMBtAJXVQNdtbBGo4GDgwOcnp7C6/UimUxiY2MDKysrsNlsUvBgRdQyv58UB7peeq2MxLVfzd+zd/vz58+Rz+eFRNXtdtFoNCQ5RHeDKBVbd5C74vf7JfLn75lcYvELlSscDqPf7+Po6Ajff/89Dg4OUC6XZXNxJOV4PEa5XMZgMEAwGEQqlRI4M5FIwOPxSPU8uz/4fD7Mzs4im80ilUrJpG6duDKRMP553X2+aWLqmCl2u10qlGjhaRCZKAT+rux+v39qNs+rDAMzCUhWrgaFWcJCoSDU3fX1dSwsLEj9JduZ6Qu86sKv+i79d51cocU9OjqSJqjslmWz2cSS8vOYWdWFGNpCkLtOKixnxHLTcuIH3cLhcIizszPpR0mloyVnC21uHEKjzHtwkmEkEpFNwi4LuVxOyus0Lg9cwpU8DW+6UmvR6zXBB1Psdrv0DkqlUlKPTG6NuDEacozH41MsR41zW1lvuh0mHq/dHSZmKpWKFMLeu3cPW1tbSCaT8j5dHGK1wfTv6Kdp+JCv0YXOwIVCEe7b3d0VN4p9G3lduscMj0K2FKnVagAgypdMJpFIJBAIBMQqc3OwoVGhUIDNZhNr0+/3BY6k/84ZT8wA8hoHgwHq9TqeP3+Oer2O4+NjLC8vY2FhAWtra7hz5w5qtRpOTk7www8/IJ/PyxQQm+2yptXs624S1CgaYbsJG8JEiOhOAtNUceDSqAUCAaRSKayurqJYLEoNtSa0OW02m0StOkXND7wqqWMVGHE3auVnv8h6vS7U4Vu3bmF9ff3KQQbm51klS7SS64hbB8Wj0QjFYhH7+/t4/vw5jo6OUCqV5BShG8NCCvrRbGvR6/XgcDgk2cYTkApszhjVNZzcMEwA0XDQOJDART+81+sJqYzXXK/XhYvDz2LL8Gg0Co/Hg1wuJ0gQkTWzuknfN/2n+eyu+r9/tOjnbeZZzP/X1xgOhzE/P49isYizs7MXdNYJQPp564QOP0hDPhQqGxWVi9IICq1VpVLB2dmZ9HZny+twOCydDDgljp9tXox5I4DLiJ0KS0vG9RPFeP78OR49eoSDgwPx04mDs8Vzq9WSZp8ka9EFYXvueDwOh8MhfBa2vNAVPvx+9p0kV4b3IZ/Po9PpyOZiSw4OZiNM6fV6pZMDu6IxB9DtdrG1tYWNjQ3Mzc3hX//1X1GpVKZadZhtO15FsW6Sm8Nna8Vnp1idRmwZMj8/L4CEvg/OyWQy1VDzKuWyWpDpFzNIs9svR01WKhXpcU7IjGxGVtqwbtIU03XhReoLZxBiTsUgM3F/f1/6t7MWk5/DjrccB9lutzEeX/Q0j0Qi0kaEjVBHoxHy+bxkUNlcSrtTzHZyooe2tnR5ut2uYPD0s3ka6Aw17yO7XTHRBFz0hVldXcX8/Dzm5+elSN7k+/A+XmUNb4qCm6JPZ65Xu9EUM06jS866Wp09dwIQyIoK+DKaKD9Y3ygyBukzEyOuVqs4OzuD2+3G5uYmVlZWJIGkm+PrU8LqQehgxerGmLBotVrF4eEhTk5OUK/XhUfCIQNsSET/fTweywgddrZluRprczmcga0qVlZWpHkR10d6MJv2MFG3trYGl8uFer2Ow8NDnJ+fS5+W4XCIQCAgwEClUpEklEbKnE4nms0mdnZ2JOje2toSlqSOV/S9sGJNarkp+LopDDCtXFbzmVPoItIl1DUBTr5Bp9kp3ABW/rr5b31TAYjfS4SBLZXT6bS816oS52UWx/xe+vt8wKPRSApCjo+PUSqVpgoTOHCMgSd7zNMizM3NYX19HWtraxiPxzg/P8fp6SmOj49RrVYl+bOysoLFxUXMzc3JZAtaeip6p9ORnvHsttXv97Gzs4PHjx/jhx9+kF6axMntdrtkVVkYzQQJOfaNRkMoxoFAALdv35Ysoil0RXVAd5Uvf9PE6kTSenIdHMkKshe6CxCTtLoJVr6fhueoZAzWJpOJNEctFAoYjUaCA0cikanPMhGe6y7a/LdmvOlqHTZZ2t7exunpqSgnE0mnp6fSS7HdbiMQCODOnTu4deuWsD0DgYAMTtvb25NBx8TXU6kUFhcXxa/mZA6SuEgmY7KjVCqh2WxiPB4jnU7jk08+kbbaT58+lVNDdwgDgE6ng5OTE2lXzQZAbrdbGlv98MMPqFarQo82hdlH4LKkUbtyWpmsuPD/TCHEq6FTKy/D1Fm6i7qrA/B3Zdd4pAkjmjWoFL6eO4xHKFvpsb+7w+HA4uIiZmZmLC3Pyyy5VaDK9QKYaooKQJI3R0dHYjUZjN+pQA4AACAASURBVJ6engrTkgmseDyOra0tfPHFF3A4HGg0GgId7uzsYHt7GzabTTg8nD5H2JQFKE+ePMHz588lNpiZmcHi4iJ8Pp+4Kxy/+dFHH+HevXvIZrOYm5vDN998I22WHQ6HjGk/Pj6W4N5ut8tU8VgshrOzM0GaCoUC3G63oETaFeW90jEWlcds03fTBv5ql9g8mV7G1OR1T+HsJvrxKkeaDqDMQIgEJ8JsZO5dx6R8HeEO1xxuNmU9Pz/H8+fPJUNps9mEmHV+fi7+MeHEzc1NbGxsIJvNot1uixvEnoHkitOX5zxU/r7ZbOLw8BCPHj0SRWftYyaTwf379xEKhaT6iS4KSV3pdBqtVgtHR0fI5/Pio6fTacnQslyPpXucbLi8vIxoNIpnz56hXq/jyZMnaLfbWFhYQDablThCIzP6eTGmGo0uOxLfJKt+nbyq22UaStG+V3En+Dqd1DGDVB4dTFZRcXgc6YW8qa/IzUbosV6vY3t7Gzs7OygUCoLO2O12VCoVGefe7/eFaLW0tIT/+I//wPr6Og4PD6cyniRi1et1FAoF6ZmYTCaFE0MWJ4swOGITgFAhHjx4gHg8LqcdGZRnZ2eSCCFuT3pzJBLB6uqqzJjtdDo4Pj5Gu92WYD+dTmNlZQXZbBZ2ux17e3s4OTnB6empQLmEMBmwmcEc0Sgq+7swRP8oeZmOUkz9eqsrNCFAEm+Yug4Gg0Iws6KjvqnwBNHZXWYUm82mBK4skD46OkKtVoPH40E6ncby8jJWVlaQTCbR7/dlnmg0GpVuxQ6HA61WC4eHh4KHk3/C6xmNRjKJT5fGUUEfPnwo/expVcnFYasHts7wer0YjUbyXUR6gsEgdnd3sbe3BwB49uwZ3G43otEostksVlZWEAwGcXx8jHq9jn6/j/39fTSbzanySpM9qoN2AC+4sB+SCM7+um+0ssj0/8j+48MjxZWjUayypG+ycCoMmYGsPNJj6RmktFotmXi9tLSElZUV/P73v0cmk0Eul8PBwQFqtRrcbjfm5uawubkpLMxKpSLt9hicZrNZGaDmdruxuroqljqfz6Ner6PVauH777/H8fGxNPifm5vD2toa0um0KDkpCZyzSh+aBK/19XWsr6/j6dOn+Oabb/D06VM8e/YMzWZTal05R+rWrVvI5/PY39+Xcr/5+XlkMhnMzMxMKToNEnMbPCHN+OdDk9e+Mh0oWAWX9NNNvPNVM3qvKmbPk3A4jGw2K73SmTI+OTnBYDBAPB7H5uYm7ty5g0Qigclkgnw+j3w+j0QigeXli5GRHL1IpMbtdov173a7cDqdknRyu9347LPP4HA4kMlkZCBXs9mUBBtPtlgsJojUeDxGo9GQTgXFYlFGP5JmTCiRLTp4krHp7PPnz4UxOTMzA5fLJVnbVqs1BWUyCNXQsJkQvEkZ1J9LXkvZacGBF0lD2jckvskEi1b0t7HqfL8+9rvdrqAfH3/8MYrFIo6Pj7G9vY2//vWvqFQqCIVC2Nrawu9+9zvMz88LDr+3t4fxeIwHDx7gt7/9Lebn5xEIBABApujZbJctNei7AxAl9vl8WFpawtOnT4U6zA2nM3qZTEYmaXAEO0c0npyc4Pz8HJlMRvxtPTU8Ho/j7t27GI8veu0QAWo2mygUClhcXJSJ48zccr6tx+OZKkDWz0Xfz/+v7NeIqbTkptBaaK6Ifs+7uKn000ejkRClJpOJZEhZQJHP5+H1enH79m1pd22324UrY7fbMT8/j/X1dayuroqi03/1+/1IJBKSMMrn8zg8PITD4RBEhejJZDIRq6onmWiuNbOxbB7L8r9Op4NgMIjZ2VksLy8jmUxOuRMulwvJZBLZbBazs7MoFos4ODjA3t4ezs7OsLx8OWqHAThdSLbVuwpxu+m0gXcpr63sZkQPXCofLQR/Zyq6WR72psIHR85IoVAQeu2jR4/w7bff4uDgAA6HAxsbG/i3f/s3bG1tIRwO4+joCD/99BPK5TL+5V/+BV999RU2NzdF0XldDocD8Xgcq6urACCN+weDAQ4ODiRgzWQyiMVicDgcmJubk+KBQqEgWVda8EqlIpOm6d/bbDZBV+7fv4+trS2kUilZD6+VqAkLOY6OjqSHze7uLtLpNDKZDNLpNGZnZ4XFykZXvP/mc/klyWspO5XaxC95FF51I7VVeVvRASqb6ZdKJYHlHj16hJ2dHQyHQ6yuruLjjz/GnTt3JBHz/PlzVKtVeDwebGxs4N69e1MDb/kdbrcbqVQK6+vrglUXCgUhXJXLZelEMDMzIwW+Npttqm3dYDAQl4VUBvKt7XY7YrEY1tfXcffuXWxubkptKZMhpB/wtKBRYXVVIBBAq9VCpVIRl4vVVIlEQuanMmDXKXeNuetr/1DltS07FVqn7K8ih5mb4m2hLX53r9eTwgrOBGK284cffsDZ2Rlu3bqFr7/+GltbW4hGozg5OcEf//hHnJ2dIRaLSbCayWSEe05/WecIQqEQUqkUZmdncXh4KPQBm82GVqs1heETiiTbUVcekSs/Go0QCAQwOzuLlZUVLC8vY3Z2VoJXAMLEZN6ClOJCoYBisSiDIhYWFvDRRx9heXkZPp8Pk8lEJg263W7EYjFhV+qmVqQP6Hpbnmav0sLwfZU3Unb9dx3pX+f/XUXRfBOhxaQC0cqzP3cikcCtW7fw+eefy3SJvb09fP/99+j1evj1r3+NtbU14bawTwyDOp5eRDSYbOLEunw+L5aXBdPsPqCTOZrLwSwlk2ycKrK0tCQnwXA4RKFQQLVaFT4OM8Tk8thsNpkaOBqNcO/ePSwuLsp1AEC5XIbNZpPAVBeyA5fup7by7+rkvcnyxgGqplha8Vf4GpOL/DYiaV+nE/F4HOPxRSs9l8uFaDQqI92DwSDW19eRTCZRr9fF6rMskJAi/WeOh08mk0LgoiIzb0BLysJnuhh6yqBWItav6lwDk2xEk8LhsDRQYmDLob/5fF42HGsNwuGwnAi3b9/GZDJBNpuVwLjZbGJ+fh52u11GQbJuldQBkvY0FEkE7UN2YYC3TCppn8+0Dj9XlE/4LBwOw2azoV6vo16vAwBmZ2cRi8UkrT8ajZDL5XB4eIhyuSwJHnbpOjg4wNnZmQzBZfkbefYsSCGk53Q6pR8jcDlynllQugSEFjmGhi1K4vG4tLnje0maYzuPTqeDXC6H8/Nz2O2XY9xJPltZWZlq0cGxN6y6CoVCiEQisqG5HkKhRMmYXBqPrXtefojy2ji72QCJlv1lR6HG6K/jIb/KGvin2+3G7OysJIFGo5E0Bm00Gjg5OZEJcplMBisrK6Icz549kxQ8rTLbb9AKM83O9ZL+y4ouWn7+sGqKQSXZhs1mU1r9sVKJP+wuwBYaVFCn04lAICCtAdfW1qREUI+24fcRYtQ8b+2D6/vPZ8c/dc+e/++zK3lZBvUqMWmZbws90iLNzMwgk8nIA6NV1vWL0WgUsVgMmUwGg8FAKpjY74UKzeKLQCAgFUjE7judDtxuN+LxuLRp4PFvt9ulUJvldZoeTYZhu91Gp9OZcnv4w0SP3++X2CAWi2FxcVE6BJNnQ9EbjVnqVqslSI/uR6n53RoqZqxgVWv8ockb4+ymsr5MeTXr7nWUXfv95r/1htNWiQ+P1jEWi01BeYQHaSG5Lk7jI7TJ7gL66GfXAW3JWcTicDjE0tJl0J9PLgo3A2kBnJpNCjFdKfLTrfgq7FJGjhCrnazam5j33xRdjWaFxVu5qC97fm+SPPy5s7ivjbNfRxS6bqEve+/LvvdVv4cjG/v9PjweD2KxGCaTCRqNhow6Z8Mhtg6hO0KFJq+GbEj2iyFFgYUj/X4fpVIJvV4P8XgckUhEfGHgMqvMTmOk8TLjSy4L60+5+TgAgb8DINRdr9eLfr8vNazk55NH4/F4ZAOZRkLXAGj0TLtlr1LN/7LncBVg8Srycyr8e0lxo/+pLbw+NQjvJRIJKXim+6BdDPrk2i1i8TOD3/F4jEgkIr3jGez1+32xrKwiSqVSAhNqyiytPBtwMtnDXo7RaFSQGm62crksLTXYy5EFKizm6PV6UwxTku5MSq8Wnoy8j3ozMKa46n1Wf/Jz3ofE1Hur7Bo/1p2v6BLQmmoXhg+X7g6TPPpY7na7YhlZ+8mqIo/Hg16vJwrPBq2dTgdLS0tIpVIoFosAIGvTLUZYckdIkGtNJBLCZyGDMxaLScE1u5Sdn59jZ2cH9XpdelJycgo5MVbku5fdS947K5/dTAhe9Zm8v28DPvzc8l4qO4Apq2neXE1K0+Qz+rK6yomBIk8K+tV+v198byqTzXZR5keUpdfrSdKKylqr1eQ7AoHA1KnB9tXhcFg6jNHtGI/HMt3aZrOJ26QpxnTFSHojxEhF11Tqt4USrdC166ggN1XBtbyXyq4TI1ZkM11ErN0c091hQQndG34eSV4sZtAZW6IvdDuAiy4A5XIZp6enYvVJs9WdhDUyAkAKQMi1OT4+RqPRwNLSEjY2NuByuSQ7XCwW0Wq1BJ7kDCY9fuZNchtWwaZVZvVl7ovOFt9UeS+VHbBmVer/M19nFodTGEBSmbVPT8vLomt2KmD9KMXr9eL8/ByFQgHtdhter1fasAUCAfGF6XqxfI4uEwcU5HI5dLtdpFIpoSGwvw37smsabzAYnGrQ9CryOlbYyhfX/7baCDeZdvDeKvtVom+8aY20tdJHPRM5LGpmRpVJHVpRt9v9Qps94KJ5697eHp48eSIuCEvlmOkdjS6m9J2enuLJkyeoVCpSUkglYXkeK5kqlQr29vakXV4ymcTc3JxkcF8F/uOf1yFaVjx3/lvTPa6CIG+yNdfyQSq7lZLrBI5MYvi7X282Wup2u0LfpQUeDocy+oUPnP9H6nChUMDs7Czm5uawsLCAVCo11cOSmd3BYCB8d5fLhUgkIjSEcDgMl8uFYrEoIyjJvoxEIjJEDLgsp9PXzuulXIW8WImVj65PQyvLftUGuYnyQSi7lWUyFV23k9akLRKsPB6PcE5Y/c9WGSydo28MQHqsk7TFFsnpdFp60ZinAJWWCnt6eiq9DOfn52U8ZrFYlPYcLDlk8bSeOK7hV51Iug4KvMo/12JlMK665++TvPfK/jLEgGlyWmFCh7rlB3DRFZfNTckUJLpSr9dlIIH2v9k8tVqtSncC9rMkEsMfKmIwGEQ2m5WAVncCZpE1mzqxXI892em+8Lqsrv86Qp6Vopt/8jVXoTnXcaBu+gZ475X9OstDpeRUOnJT2IedD7fRaAgEyA5msVhMCFzn5+fCjuRm4QBgWufl5WUsLi5K/Sj5MMy4MqEUCARw69YtOJ1OmTNls9lQLBaxvb0tp0ipVJJmS3Nzc1MTUYDL7gDap77OGr9KtpM/1/FjzC66OiPLTX1TGZTvvbJfJyaEpq0SHxCnzgGXozFpRXUnM54GwGWHYvr05NdzyAJwSdLSA6wYF0SjUayuruLk5EQ2YaFQQKvVEjoAiWBLS0tIJpMvKNBVCvVzBIs61iG3yCyo15vgpsp7q+wvc18YXLEogUkdTcHlMF8O+iXeXalUkEgkZFhAJpNBKpUSJecso36/LwPXmPInmgJA0vZWKXieIKQylEolbG9vYzgcYmlpCVtbW0in0wiHwzLxw2Z7scjiTTOXV7k6+k/SMhjDMNYhwY73mFZeF9TfRHlvlR14ucLzSGVQR8vOOkyOmAEumIjNZlN6MlarVUnbz8zMYHZ2Vvz7SCQiRCwWNDPo5EPnBtNrZa0n3Q9O6eA0D9KO5+bmZIOZ0wStOOq8D69Kz71K0c1AXxe204Wz2WzSQYE5ivcFgnyvld0qGDX//7oEE7tvEXrk7+jjc0pGOBxGOp1GMplEJBKRYmiSudiTkQrA0jtNBqMy8Xfk2adSKRweHgqSEwgEsL6+jkwmIxQFAFOcdPrVvBZet1kHbBW8vuz+6NcwN1CtViWYZpUY6clWc1ev+rzXfZ5vKlcF0e+tslspulV62+q1wCX/nX40eSuhUEiKt0ulEnK5HCaTi+66MzMzmJubk9GN9KvZ50Vj9jabbUox9fpIPmNbPAbHy8vLmJ+fx61bt6Q/DK+HiS8OLNPug9kSwwoPt0rtX3dfGctwqESxWJSJfsw461OFp44Vxv+qclVy603E6jPeW2U3xbRor3KsMohknShZiJyOx3GRTNd3u10Ui0WZZ0RKAauXqHQs8dMwpUYqqKj8O1EavSnM9Vu5KmZG+FUyqlZQpG6lQTes3W5jf38fT548QafTkTmrqVQK8XhcWJk6UNafr102q81otVa20ebrrO4X369Jfvr561PavHcflLK/jkVgLSjbRPOH4xw5nsblciGXy6FQKKBUKuH4+Fj6QJIsRtSGkKOu5xwOh/J68mz4sGgZSRqr1+sol8vSRYwnAIApRAeYzgpbXf9VmDrw4ngfXZYHXKBNpVIJOzs7+PbbbxEIBLC1tYXFxUWsrq4K3m8iW9q94ueaya7rnlG73ZaW4/rkpbukRW8q4HKaN11JqwZQH4yyv4nowmOK5svMzMxIIXQsFsPJyQkmk4kMMPb5fFKfyodiWhWTb0/RaJHf70cgEBD6ri7Y1q/XCm1adBP31t/3sgBSW0xOBN/f35d2HsFgEDMzM0ilUgiFQvI+s6c7Nzr/bvLqtXUGLmgZzWYT1WpV6MucXUV2J2MVDTRYnXj6+/VoGf3aX6yysyBZZzd17SpdlKWlJczMzKDZbCKTySAQ+H/tXdtPW9fTXceB1GADNgSsCAytCg9t0+YpT/3TK/WlKlIbpaUVDSlFiVNiLjY33zC1sf17IGuyzmQfh0Ck70tgpCiJ7WPvy+zZM2tuGVQqFasvw+bCTKbwOaOU/KHQY3U0sa0NVSumEOr3kJShvRNHjeAkSe/VCdbJAS4YcHt7GxsbG2i1Wta0TBum9ft969rNMGkeNG0s52FSz+gsFPvs2TNUKhUrB86aldoMWm/EYQ4yjWXyc7+xzA4gJg3pNNHCSEzcSKfTGB8fx9nZGV69emU1F2mQEZlhEBfDhFV391JXk0IYqsu0P5bOo6QLOZCSjDlvjPr5cq6ecVKplBmk5XIZ5XLZejcVi0XzOyiEOgzd4e/wdc6h1+tZ2W02XXv58iXa7bYxOLuN8xkaw/4mSZq/dshTutHMTmJXNa+DqnrDfzNUIJvNWpkNBpGx9SWbCFNq+u7dVD+0rJ5KdmL+p6enVvcmiUJ6sDdc/XsKUXJe/f6b2u87Ozs4Pj42Dy6rEwNx+Jb/59+qalDC8jcYytxoNPD3339jbW0Nq6ur2N7eRiqVMkRrbm7O7Cb9flJIFfTvJalsN5rZQ0ZeKLZDHVGs+UKpzFJ4qpvzmSQJq0QGYS4pvZSs/0K4b5h0v+rc+XcUXYRDVCoVbG9vo16vWzbU/fv3MT09HTtwequpBNUbTG8MABZMt7W1hSdPnmBtbQ1//PEHzs7OsLy8jGKxaL1h0+m0qXk0TodVLfMHLknVubHMTkOQVyOt/ZBUYGJHo9GwjnfK7F6/Vt07lC6n+i0RIY4hnU5jMBiYd7fdblti9WXRpmEGqTfIicI0m028evUKpVIJALC0tGRxOaxHo6rP6OioxcoMBgNjSM47iiILie73+3jx4gVWV1fx5MkT/Pnnn9bMeGFhAY8ePcL333+PhYUFTE5OGqxIQUDdPakUix4uj8Yo3VhmB95IX0qqJNIwYbZ/YaIz8Ea1IXGxFXf3agWNKUZGkjkGg0GsOjH/TaNZKaSivMuIU+mrcf4nJydWApw1Jefn52PdSPibqspQP9aQDFY4S6VS1gnl2bNn+Omnn/D48WOUSiX0ej0rSfjdd9/h4cOHMUbXqg+aWONRFq1Qx9dvJXuACI2F1BZFaVTVIMJAw1LLZShxwdkEmYyoDMuKYtxYlgBhjirDk33Zaa+remPM4+henfIHjozOzt8zMzNYXl5GoVCI4fwc/7swfJWs1WoVa2tr+Pnnn/Hrr79ao4i5uTk8ePAAjx49sorLRIU8fKqYOdEeBQcAJEp9pRvL7Nw4b8R5PZ6Shs9QwhJmpD5NvJ1NAVQChiITCS+2Wi3LVmLFBEp8Gs7aE0l14RAje6mmerU/BBwDGx10Oh2MjY3Fyl1zrPwNXx7PG6p6c9AYXV1dxePHj/H8+XODBGdnZ/H111/jm2++QaFQMJtgWCy8wrc6D09JtsyNZXb1+nkp6F8nI1NC07OXTqcxMTFhCSEHBwfWVIw3ACuBAXF9ud/vW9zJYDCw0nZkklqtNjTex/8/CYEhU3umpM3CCgYHBwdWFZklv3lQaSxSnaOPgXaG3oL8jf39ffz111/48ccf8cMPP2Bzc9M6gOdyOczNzVnreXYHDKFOerj0QOmh8vuaBAzcWGYH4jAcN1bxY0rETqdjLWOAN+U3CB0SNalWq+j1esjlcjGjMrSJrVbLytwxrj2bzaLf79sB8AnVIeLYvRqlc0w6BJ1Ox7Kxjo+PMT4+buiLbx1J45PMztdC6sP5+TlKpRJ++eUXrK6u4rfffjOJznDoe/fuWc35kZGRWMMEEvdDhYSqll6d0z29ZXZHaszw316SMjiJRU7ZSYNRktls1kpvVKtVY4Z8Ph/sZjEYDHB4eGiOm9PTUwusymaz6HQ65pgiA4c21RPHHpL+IWSGsUEs2dFsNq39JAuwhlQWoiv0S/g28WdnZyiXy1hfX8fvv/+OUqlkjK7ZTaOjo9Y4gsLA14n3hzSE73uj3d+GSjeW2ZUJkmA6Stdut2vwIh0kLJo0MTGBiYkJnJycWHVeDfVlogOp2Wxid3cX5XLZSuUx0ymTyVhtderrOlY/Nr73rs+E0Akyu5bVY3EnLRniD5lWV/BIFm+lf/75B+vr69jY2MDBwYGpG2RiNnyYnJyMtcDU1MfQ4Q7NMaTK3Ur2AHkHCKWpz69UI48bxqv83r179pmDgwOcnZ3h+PgY3W4XtVrNkkN4S9TrdSuHfe/ePdNfGVND1UdzV3WT/WYOQ0c8s+vnmJLIHFjq0wy+0jAHqi9UJ4YhH6y4UCqVsLOzg0ajYYhVp9PB3bt3sbS0hC+++CIWVKaAgR5OP3d/e6nxHYo/Ur3+RjO7nn4abPRYaoSdLjzRGMKFzEElgkImYgVgVY8IQ7bbbWQyGXz++eeYn5+PFT7S2pIhnV1jeDi2pBj3EO7O24o4PoOmVDemLq7IEZPAte2OlvPg/w8ODlAqlbC7u2u9rpQ50+k0VlZWsLKyEishCCB2wDy6k7Rnntl5E4ek+41mdl1EZWglMr1Kfa+Ls0HwYDCwJA86hLwUZjhvLpdDoVCwpmIk3Vzqxj4jCEhOPVMG9ckT3gFDyZ5KpUytYIMGVSM8k+t3cIyjo6Oo1WoolUp4+vQp9vf37XkdJ1Mc5+bmkE6n3xp/yO5QelciSLPZtCbQWpIcuGX22P/JyCopuZhUKyj5vGE0PT1t4QP8w0AuSlfmp9KwVYmuRAalhNcgNQ+5JTE8bxKOl//nOFixgDcZGx8wmM2vS0gVojTngTw6OsLW1haePn2Ko6MjjI2NWYVk4KJqMftbMTNMmVvRF5Jnas4tZI9EUWRqIhu2MVEduOHM7onGVlIYqerL3jBjyK4apux3xO/W+BcyvSeqEjx0ISmn0tpL+mEhsIpm8NoHYHE+DMDy5H0PHKN+H+N8jo6OsL+/j0ajYYYucHH75XI5g2WBC/g1lUrZXIcFcYXG5OdINIiChjE9tzp7gLx+S6I0jKLI3Ph6jbM1I5l0cnLSMHN+r4+u9IysEo6OKGUCz7Qed9Y8Um264O0N/R6Ol/2Yoigyb64SGZmHiQ4ljoM2DG8i+iP0sBPpyeVyuHPnDs7OznB4eGi9onjbhdLvkpjfS3juBdUXHlCO4ZbZX1PImCORUVKplBl2SV5NvqZXLhndqyMaQOWNstHRUQuACknrJKPUf8Yb2EpkAnqDqVYAb6IhdUx6c/BzhEj5e8y8Ojk5icXsRFFk/gmiWd1u19SskDp3GdJ5E6dXO0eFzC2zI2zshCRtFEUG1SksqKoPJQuNVG1jY4v+enMZW8PwWJIiIknM7klVimEHV+dMe4DqFSV/r9ezgkicW0jFoRTvdrsWe14oFLC0tIRut2sFqABYyILeOrQVuAbDxqrz5txUcuvtwmdumT1AIWZXQ4mSFoA1/w0lQyusx5LXGrVIaUlD9b///rOOeb5qgOrHScyt4/ceVH+zeOnOsWrObVIlAD04IcOYh4I5uw8fPkQ6ncbe3h5OT08xMjKC+/fvY3l5GYuLi5iZmTHIVpl9WJh1aEw6R77GtQ1VKrtl9tekC+ZVAtXZ2+22BS6RlJm82sI2ktT16UkcHR21+olaf4XXsEdhhlGSmsKx6Y3iD4mqVWr4qiRnyITeGFqfhYFhvV4PX331FQaDAZaXl3F4eIhe76L79uzsLJaWllAsFrGwsICpqam3DNMkr+mweeszrNA2OTmJ09PTt27dW2bH2565ELNTUrAVDD2OwPCkZ2V+xdxTqVRM2pPU8aR15N9FOnY/Fv6Gf89j+vq+twl8JCjtAVW/xsbGsLi4iHQ6jaWlJXMqscXl7OyshUWEdHRddy+1k+bsx5TJZDA1NWUdTm6Z/T1JkQyGxdJ55EtJ8PP8m7cC8AavpkFIFUYTstmhm9CdxosohaA3kg+LDalDagQTg1dfAhEnHgiN3FSVTV+Logi5XA7j4+MoFAqGxkRRFENbaC/4G4meXPXgXhaG5GeJ5Z+cnOD09DSW5XTL7AEKMQb12n7/omZKs9lEq9WKhbmGpKs+C8BCg9nenR35+BwriDWbTSucpCXh+DnvDdX3/FySHEKMg2HZDk0v9BGXITjSx6GkUikLkmMIBWFAvhZFkdWr1Of4nbyFknwMfq7eHmFwHvvY6trfMjvCSRHeXU4JQSyapa3Hx8dj+ZeMzaCUJNMQYWENmkwmSixqPwAACIlJREFUE8t04vODwSDW5Lder8egTpLPCeXzHmpU55OfJ5Ge09NTsxU4Hp1/iOmGOYB6vZ6V/aZ0Z515Qo+aJabf4UvXDWN4Va94OHhr0ki9VWMuQV4KMmGDiQZk9nw+bx7BkFTVjnxaAYzJHf5Q0eDj7VGv140ZScMke2jsIZQjiiKTwsTKG42G3SjA8Hrv3tAFYHBjvV63xBRmIJ2fn1u7+aRD4g99iLyq6IPlaDhToutv3TK7kF6LITWG1z4DqOr1OtrttmXFU7JkMhnrTsHn+UdDZL1hDMAkH6uC1Wo1a2fjwwsuY7gmURRF1myhWq3i+PgYGxsbqNfr+Pzziypg+Xz+recYGkHqdrs4OjrCzs4Odnd3UalUUK/XY1XStFs4VUGFMDV82kOcOteQI8871IbBtbfMjnhZBm6mDwZj44J0Om34OY1UNgijHkwXPBlZCwqpJ5UHS6UP81eBC2OVQWXD0B8gfHBCpHOcmprC7Oys9Xzd3NzE5uYmvv32W/udXC4HADF0iAf6/Pwc1WoVpVIJ6+vr2NzcxM7ODtrtNqanp7G0tGQ1MLPZrNkmdLINM3S9euYrKCTNMwkJA14z+2Us3ptAujDK7Ior09NITyn1RZJHGNQ4pIrCTdb4Gr6v+jITvRkurHErIbiTTKy+AoXw9DVK3fPzc+vqXS6Xsb+/b9J6enoak5OTsahJ1rkh9t5oNHBycoJqtYpGowEAmJmZQbFYxJdffonFxUWL2ef30EDVxBaOjZ7WJOkdMrT9enAttHYncCvZY6QMo0TprG1p6DDytwAPjOZTqtGlSAM3mZKesBwZn+X2mElEWNAbofq7Xhp6LJ3fzfmwyx/bXFYqFbx48QJbW1vmhh8bG8P4+DgA2I1G4zOVukgr5C0xPz9vddzZKpO6OgAz3jl2Velo1IcSudUg130J2Sx+H0yye2eHbnzoJH2K5CWtLqCWfSOzR9GFJ7XZbL6FgasU53d5xvQb5teXB6RWq2Fvbw/z8/Mx55OiEOqk8r8RQpn86/RuapbW/v6+5dTyZuFB4QFi8zNfLWBxcRELCwsoFAqYmZmx9js6Bi0/ra/7OSj5vdFQ69AtoMIkyOwey0364U+RdDEV91UvnEocog5a4xF4OzCMr73rt3XteaharRZqtRoWFhZiFcEosQaDgY3HY+kehRmGyuRyOaTTaeTzeaysrODw8BAHBweoVCqoVqtoNpsWGPbZZ58hm81a+Y98Pm+J09ls1hJAKBRCB1krAvv3Qvi6Fxg6fz5DUmbnc4mBYCFdkAs8zNL92EhPfNJ1GFJruHisOKCS3Qcq+e9SUintvaGZTMYq51LC+sZh1P9D3/k+a8D9JOY/NTWFQqGAk5MTHB4e4vDwEI1Gw1QWOm1yuRympqbMgUOkKpSQ4seYNM4QnOnHSgqpNWqUBjH8kPULxKUNHQ4A3qua7P938kU5NQHCX7W6kBqs5fHvy8KB3AwPvQEXFbOKxSL+/fdfVKtVazZ8dnZmjcZGRkbeOohXgSKViah/3717FxMTE5ibm4slZFPPJ46t0ZIfUgjqmnhvtAoJ/z4Qv/U8X8cke5L0SToQHzN5HVEPN1/X0g78HDeZ6osXEFchr8ZMTk5arcVer4dGo2HwIOvQhBjsQ+wN1TjCp/8XpPuRhLz4vQHejtz0tuhI0glR8nrRp0Le4g/NUz/Da3psbAy9Xi8WZHRV8rr0YDDAxMSEVebqdDo4OjrC7u6uoRt8LskTeVVS6O99D+4wj+5V6F3qTqikIGNz6JijzWXQo8Jf9Nhls9nEsNBPiZL06hCKoY0DSHyN9ow6fi77+2oTAbDMJsZ2nJ+fo16vY3d3F3t7e9bmnVDkh7h1aYcwbIDQpI9/8c4aLyhDxvl1yfMg/+89pgy7ZuAc4Vx1Wo0wxLPdbqNSqeD58+d2falOqSf3Y1dl1Fr3MKNa+FwoMkO5XDZ1goJhZ2cHuVzOcPGrkKIGTPCo1Wp2uJrNJsrlMkqlEqanp2Mbys0Owcfvux4hNET3X/kAeHO7qI2jSSfX5ROFD6myKFLmD1m320W1WsX+/j6azaa9Z2gMs03Oz89xfHyM7e1ta/akk9XovY+d2YE4Hs75qMHKwviaa1qpVNBsNg0Z6XQ6qFarePnypW30VcbBNeU637lzB61WC/1+H5lMBlF00XirUqlgZ2fH6r2Q2b1Ael8iI/E24WvK4HSSeQSLNowmt2jzhesQmVvVKwpnPxY6+lggqdvtWtqfRT3yNPf7fTQaDezt7ZlU8384gE+NyPiKXdO1zUUeGRmx7BdtI3N8fGybeh1mA95sLqXUnTt3sLCwYK511oBnIBoP3YdQNVVKc0yhOBOvPqhRGEVRLKz5uuOhSuTzd7lXyuwUTkdHR2i328hms1a6w3qpMo2p1WrZl2gZAt0Ivv8pkMfZ9bqjW56f0UwjNhvQGHfWSbnqOLRVOzet1+thZmYGDx48iLWfjKLI6kpSzaHqdR1B5IWa0jB7IOQn+BACkbymhqbynx5Aj2aNjIyYv2B6etrK7I0Ui0UrgcCN9QYJJZs/UZ8aee8br3DGog8GAwv+onS/rmQls1N6K7Orn4PoD8OG2aLS9FHx7r7PeLy66nVyIJ6ooYzv1ZyQR/Oqa6I2BOOQOE/1fVDiM06ejr6JiQnk83nk83lj9qjf7w/osCCqoAYaN5tXgS7wx0x+47znDXjjoKAU15ACMlZSjuhlx6DMzswaGnlM9Oj3+7Y/VDlpoHI8Wi7vqocvpPerquJvD9XlfUWy64yDQodOK0ZbArDXdO0AxAL01KnEBJUoihANXo9IP6QeOuqOimt+KnBk6GrWualhzs0OPXNd1U49qKlUyrDhUJVbjjFkoF1XffAqSZL3MvScCorrjkNtJ6qXKtmV2QkK+MrK2iyB4/kfUEORjHKcErEAAAAASUVORK5CYII=" /></td><td style="text-align:center; width:250px"><img alt="" width="120" height="116" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAALsAAAC0CAYAAADMxl2/AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAB3RJTUUH5AYQDTcG7+THWQAAIABJREFUeJzsfWd3XNeR7e6ccze6GzmSoAhKoiTKQTOyZz7Nzx57jccztjSyKIkkCJDIDaBzzuF9gHeh+vACjLJB6tVaWCTBDufeW6dO1a5dVbZ8Pj9pNptot9uw2+1wuVyw2WwYj8fo9/vodrvw+XyIx+NwOp1ot9vo9/uYTCaYTCYYDAYYj8dwOBxwuVzwer1wuVwYjUbodrvo9Xro9/twOBwIBAKw2+3o9XoAAK/XC6fTiX6/j36/j+FwiPF4DKfTCZfLBbvdDi2TyQTj8Rij0QjD4RA2mw2BQAAulwuNRgPtdhs+nw/BYBCTyQT9fh/j8Rjj8VjeCwAOhwOTyQTD4RCTyWRqzVzDZDKB3W6Hw+HAeDzGYDCA3W6H2+2G3W6X99rtdthsNrkfk8lE1mqz2WCz2eQ1FH6+vh5+lvnD9+nPBSC/53f3+32MRiM4nc6p6xuNRhiNRnItvKf8HP7eZrNhNBphPB5PrVn/6PXztfpemdf5usJr4TNwuVzyXPr9vjw7rhmA3DteQ6/Xw2g0gsfjQSAQQCgUQigUgsPhgDOfz+P8/ByVSgV2ux0ej+cFJfN4PGg2m7DZbOh0OhgMBvJF/X5fFIHK7vF4MBqN0Ol05P89Hg8ikQgcDgc6nQ5Go5EodKfTQa/Xk0V7PB54vd6ph8gH6fV6AQCdTgfj8RiRSAROpxP5fB6VSgWhUAixWAx2u33qgQyHQ1k3v5fKTwUZDocYDoeiBPrBTSYTWQfX6XQ64Xa7Rbn4XXy9+X69Fn4WX2+z2eBwOKZ+9HOgUmnF0EqoFcTpdGI0GqHX62EwGIiyu93uKaWmkQoEAnC73XL9VHZes6nQfPZUet5TKqBe5+sour7P2ujxWvSz4ndxbTRKrVYLw+EQoVAIqVQKwIVRdTgccB4dHWF/fx/n5+eigDabDU6nEz6fD36/H+PxGM1mUxTP5XIhFArB6/XKQtrtNrrdrjxkbSVcLhfC4TCSySRcLhd4kvR6PfkZjUZwu93wer0IBoPw+/3o9/uo1+totVrodDrw+/2YnZ2F1+tFq9XCeDxGOByGzWbD0dERzs/P4ff7kUgk4Pf7px4ulV0rKq91MBjICQVA/p83nkpdq9VweHiI4XCIbDaLWCwGp9MpD8nKuvOB0DDwtOz1euh2u7DZbIhGowiFQi9YU24QKiF/9IaiAoRCIQSDQXmww+EQ3W5XTiBew3A4lPvZ6/Vgt9sRi8UQCARk7R6PBy6XC91uF41GA7VaDfV6HQDg9/vh9/sRDAbhdrvlHnFdvHdvI6ZBGQ6H6Pf7okvaEOiNOBwOUavV0O/3kUwmxaPw+/0XXkQ+n8fx8TFyuRzG47G4Fm63G6FQCKPRCK1WC4eHh2i323C73QiHw8hms3LDu90uSqUSisUiOp2OWAe32y1uBQC43W64XC60Wi3UajUUi0XU63VRKL/fj3A4LMrRbrdRLBZRLBbFajscDsTjcXS7XYzHY7HQhUIBuVwOLpcL9Xod8Xgc8XgcLpdrSmG4GanoNptNNh83Oa0j30frUigU8NNPP2E4HMLtdiMQCMhG1cpnKrp2CTudDlqtFtrtNprNpigmHxjXR0XnRqSVpqXWbpDX68Xs7CzcbresezAYiBunT4jhcCgKzO/n55ivq9frOD8/x/n5OQqFgmyMZDI5pdR8Vv1+Hy6XCx6P540VXRsLniQ0VDabDcPhUFwW854PBgPUajU59WmU4/E4EokEnHyTy+VCNBrF7OwsgsEgPB6P7PBarQa73Y7BYIBoNIpEIoF0Oo1AIIB+v49qtSp+b6/Xg9PpRCAQEIvh9Xrh9XrF351MJmg0Gjg6OkK5XBbFCQaDCIfDiEajCAaDaLfbODs7w/HxMQ4PDxEIBDA3N4fZ2Vm5ER6PRyyU2+3GaDSS1y0vL8vJpP1LAOIuTSYTsXQOh0MURluO4XAoLlkikYDD4cDdu3dx+/ZtsTparHxcKiyVvN1uo91ui3/p8XjEYml3gevW7gTdDJ4EXq8X8Xgc4XAYHo9HfFeeHG63W354TyuVCprNJtxuNxYWFjAzMyOu32AwQLvdBgA0m03E43H4/X6EQiHMzc0hnU7L6UnLzk2vN8GbuDNW95Frstvt8mxMF5HXXCqV5Nrq9Trq9bq4pk6fzwefz4dIJIKNjQ18+umnSCQScLlcGA6HaDabqNVqSKVScDqdyGQySCQSCIfDcDgcqNfrKBaL8Pl8iEajsNlsCAaDSCaTyGQyEpQOh0O0220JCDudDiKRCMrlMiKRCOLxOILBIAKBgCh7p9NBPp/Hs2fPJBBdWVnB0tISotEofD4f7HY7Wq0WwuEwEokE6vU6HA4HVlZWcPfuXUQikSm3QD8Ebrxer4fhcCgnGm8k/cJyuYzDw0O0Wi2sra0hHA7jV7/6FTY3N+Vk0wGpVkZ+H92YbreLdrstm6fT6aDRaKDb7UqQ73Q6xTfVSk1flevkaxnI6eCUys44h8ao2Wzi+PgY5XIZrVYLPp8P6+vrclJ3Oh2USiWcnp6K2xWLxRAMBpHJZLC6uopkMgm/3y+niL72t1VwregUuklUdqsg2GazodvtolwuI5fL4fHjx8jlcmLlAcDpcrnkgYTDYSwsLCCZTGI0GiGfz6NcLqPb7SIcDiMWiyGTycDn86HX66FSqaBUKqFarUpQEAwGkUgkEI/HEY1GZdPwxmu0w+VyyevT6TR8Ph88Hg+CweCUO9FqtZDL5dDr9dDpdNDpdJBOp+W4ZFBaq9XQ7XbR7XblCNdH3lXi9/uv/f/hcIiDgwOcnp7C5XIhHo8jFArJTfb5fC99eE6nU66NQTtdDboAdKN0gKqRESo+N4UOZs1rZPzDE4xCAIIKxOAVABqNBvL5vPxUq1VMJhNEo1HMz89jdnYW2WwWgUBgSsnogv1cwhP3ZeLz+aZOZt4znjROHYh5PB7E43GxDtVqFc+fP4fNZsPm5iYikQh8Ph+GwyGOjo5wdHSEYrGIbrcr1jwejyOVSskRR+VkIDoYDDAcDgWSZCBMy81jiwvk8enz+UTpbTYb4vG4KNlkMpH4YDKZSDyQz+dht9sRCoXkZhEupd9L/10HVXQd+LtcLofvvvsOxWIR2WwWoVDI0oKZaImV0K1gHDCZTBCPx194vdX79efro/wqS8cNo5GhdruNSqWCQqGAWq0Gr9eLWCyG4XCI4+Nj7O3toVwuo9PpAAACgQAikQhmZ2eRSqVk49C1IIrG58f/M9GoVxHtoum4hS4cN7n5HfzpdDpoNptotVoCeHg8Hnn2To1QaPio0WjIm+haBAIBdLtdVKvVKavvdDoRiUSQSqUQjUbhdDqnlHs0GslDBiBHOCHGcDgMv9//woOhBAIBhMNhVKtVlEol2O12rK2tIZ1OA7jY+ZFIBL1eD8ViEeVyGb1eD7VaTZAd3kwiRMwlWAm/fzAYoNvtolgsolqtYjweY2ZmRhChqx6YiYXz71o5+VDflXCDautvhfF3u13UajUUCgUxBna7HfF4fCoQDQaDiEQiSCaTyGazSCQSCAaDoh/aajIm0XmHN8Hbr3oP79N1bpJ5rVybjr+cDGK8Xq8kfAaDAU5OTtBsNhGJRJBIJMSPPzk5wenpKYrFIgaDgbgQc3NzmJmZEd+JAQKhrEAggEAgAKfTKb9nMBqJRER59LFKcblciEQicLvdKJVK6PV6otAMyMLhMJxOp6A3tPDchPxsbmyiIFR+qxtXq9VwdnaGYrEIu92ORCIhMQMRJivREKSp4FZJGroT5kM3N4vV5/D7GHfQmtGya2HcVK/XUSgUcHJygn6/j2aziWg0Kn7x7OwslpeX5ZnSEGljRECAJxQNGOOD15WrDAS9DHMTaR3h77QLaLqCAOAcDoeCghC/LhaLeP78OQAgk8lIcNrpdKYgq2g0KrBOLBaDy+WSgIsuisvlkkCSGOh4PIbf75f3BwIBuSjzgvlvv98Ph8OBcrmMarWKk5MTzM7OijvD1wQCAXg8HrTbbQl+Ce0xKtdZOFNpdPKkVqthd3cXhUIBwWAQ2WwWs7OzSCQS1/qQL3NB9PH7NqJhSn6v+Zk6mWXmSRKJBEajkbifRLcymYygLuFw+IXP48bU1p1JnTe9puvumdVpr0EG/RkaFNAoHAA4J5OJHFGBQAC1Wg37+/t48uQJFhYW8PnnnyMWi6Fer6NcLqPZbMJut2NmZkasZjAYlGRFpVJBo9FAIBAQGNPlciGfz+Pp06dot9vIZDJyg4nqmP4acAnZESkBgEqlgk6ng/39faTTadn99CW5o4lpx2Ixecg6CNTpcyoMLSwtU7lcxpMnT9BoNDAzM4OVlRUkk0nJ7vIUMq2uqdhWCSf9Ho3cvEwBzAeu4wsqHYX+Lu9hv9+H3W4X33tlZQVerxfz8/NIJpNTwSY/j3Ci+Zk6l+JwOF6Alt9GtPExN5b25a0UnveY181rB/4eoHLx1WoV/X5fcHX66i6XC5VKBeVyWVyGaDSKaDSKcDg8ZdG73S4ASMBI7guPOZvNJq6P9gFNazcajeS4LRQKOD8/x/HxsQS7p6enODw8RDQaRSwWe+FG6USSuYmucg/G47EgPq1WC2dnZ5K5XVxcxOLi4hQKY7oq5mfqz33Zw31Ti2hyWXgv+Sf/rpXe4XAgHA7Lc0in0y+cVPTBdVbZvDarBJD+/p9TXvYdekNIptnn8+H4+Bi1Wg0+nw+JRAKBQABbW1tYWFgAAJRKJRwdHaHb7UqwopNIzWYTxWIRtVoNbrdbEg79fh+lUglnZ2fo9/tIpVKIRCLIZrMSyHJh5uJHoxFyuRy+/fZbbG9vY39/X4LEYDCIUqmEvb09LC0tvfAAGLm73W74/X6B25jeNn1Zit1uR7/fx7Nnz/Ds2TPU63Wk02lks1ncuXMHmUxmCsZ7VeLTy5T5bY5+Uwlp6flvnQ1m5rZcLsPlciGbzSKZTFqm94nSmevjycjvfZMT6XWvz0qxrwIzzPe/AD1Wq1UcHR0hGo3C7/cjk8lgaWkJkUgErVZLoCgdpTPAY0aw2WxiMBgId8Jms0nCqVgsynGZTqcl7Q+8SHAiD+f09BQ//fQTvvvuOzx79gzlchk+nw9ra2sIhUKo1+uoVCqoVCqo1+tCPiMKRBzf5XJNPTRCjxqRoTXv9XqoVqs4PDzE/v4+QqEQ1tfXsby8jNnZWcGXr/ORr7rpP5dY+bLa2nKN9Kl5yhI4IHzL4FQjH1brfhexxquKdgvN0/FlSq5/BI0ZjUao1WoolUpIJpOSPGDyo1KpoN1uIxaLCTFMWxGiLgAED59MJmLt+/0+wuGw4O/hcFiSGr1eD+PxGD6fT5S/1+vh8ePH+J//+R/8+OOP2N/fh91ux+3bt7GxsYFPPvkEdrsd3377LarVKs7OzvDs2TN0u1243W5R/sFgAJ/PJ9wet9strk2j0RDuRLfbxcHBAXK5nBCnGo0G/H4/5ubmsLq6Kok0ABLsmqzEmyJXIT4mQmSeSm9Lz30fxEneR6fTQSAQwPz8PFKpFOx2O8rlssBujMypNOSrdzoddLtd4bYQY6/X66jVavB4PJiZmUEqlRJmHxNKxN8ZhDCV/d133+FPf/oTjo+PMZlMsLy8jPv37+P+/fvY2toSC7yzs4NarYbnz5+j3+8jFAqhWq0KHXQymaDdbuP8/FxOpsFgIKeQx+NBq9XCo0ePcHBwAJvtguoQDAYxMzODpaUlZLNZRCIRAJdxwM+dMXxbsVJ2TcfVFFnzPe+LvElc4NRwWygUwszMDMLhMOr1urgEgUBA0v9MtLRaLbRaLaFR0up3Oh2xroQY0+m0ZGbJvRgOh0IwImvxhx9+wDfffCOui8fjwdraGj755BN8+umn2NjYkOTR+vo6xuMxcrkc9vf3hbDUaDTESvV6PeRyORSLxakCBfLpHQ4HBoMBcrkcWq2WkMcymQxmZmaQTCYFT2cQr6mmN1GuUlqdidRwoX7fhy5O+rbMUjI5w+QSqbd0URjVM9ix2WzCabHZbMKBHg6HgqVHo1G43W7J3pXLZUwmEymyKJfL2NnZwR//+Ef84Q9/QD6fh9vtxsrKCj777DPcv38ft27dwszMDIALy7SwsIDxeIxyuYzT01OhgXo8HsRiMVFskoPIV9dVS/pavF4v0uk0bt26hfn5eVkbMM08NMlkN02uwqutOOc3+XT6OcQJALFYTJJEk8lE+OaTyQQzMzOCnFAxWq2WUC5Z5UIuDRWdlSKJRAJ2u10sOk8MQpLlchkPHz7Ef/3Xf+E///M/8fDhQ6RSKXz66ad48OABfv3rX2NtbU3gRVb4RKNRQXjK5bIwAefm5pDNZuU7SQwjOYxrHg6HKBQKgtv7/X7Mz88jk8lIXAFcBtC05hpeM7nV/0y5KiEHXLpfZgnlL07ZbTabJHeCwaBAiY1GAz6fD5lMBsFgEOPxGO12G7VaDa1WC8AFy4w4O1EXUlXj8TgWFxfhdrsl88riDiID5B7/+c9/xh/+8Af8+OOPaDQauHfvHn7zm9/gt7/9Le7evSvcFhKP7Ha7VCTNzc0JjTMajWJ1dRW3bt2C3W5Hs9kUa0wuudPpRDKZxHA4xLNnz5DL5VCv1+FyuZBOp6XMj745XTwqtS4GYcxxFZT5jxYrheemJMOS7tsvUtmpOHxoLJez2WxC0mJBM8uzaFlZmsXyuXK5DI/HI/SBQCCATqeDs7MzQUiI03Y6HTx9+hTb29v485//jP39fYTDYWxubuLrr7/GgwcPsL6+LoquayapXD6fD4uLi+Jeeb1ezMzMTP0/kROiM7yuyWSChYUF+Hw+nJycCMtvMBhMkag0L4NyE5XkKgKatupa2X+RbgxTvoQDWWBBngmJPlT2brc75eMzWKXFZ4VSMBgEYU2S6FkBNR6PUSwW8ac//Ql/+ctfcHR0BJvNhvv37+P3v/89fvOb3+Djjz+W4JD4MABJT1Pm5uaQyWSmCn/5HmLHtMj01Ul+i8VicLvdqNfrUkPbarWEI3IVHMcN8CY01p9Lrsrm8j6wEINUbtKpf0nitNlskhomSYvICglVZDHSemqGZK1WQ7VaBXCBs/OU4ObQUCCris7OzvDkyRP89NNPyOVy8Hg8WFpawpdffomvvvoKt2/fFkUnFk9XgorOdh5USs1z7nQ6clJpshdhUyo9kSWWlHFTWJV+aY4G/3wf4DrTspNHQwNHuUkb9+cSp81mk0COvWFIp2W6v9VqCW89Go3C4/FIQW6xWESz2RQUhCV3pVIJtVptqgWGzWZDqVTCX/7yF3z//fc4PDyE2+3G5uYmvvzyS3z99df45JNPJFPJ+MHhcAiGD1w8QMKHAKZS+MwZsGBcP1CdIWRwzIocIk9kTWrhxtCfcRV56yYJNzWVndegW4BQaFA+ZIV3ApeBn4YR6b9riJFlZQ6HA8ViURSavPZIJILBYDCVyvd4PEgmkwCAer2Ok5MTbG9v4/j4GIFAAIuLi/jyyy/x61//Gpubm1MlX5p7rtER+v5WgaFOEfM9fMj6c7Siah9Ww5J8+JprclMtuhXJTSs7A2oGp9qyW/HvP0RxanaYrv8k54UtK1iYzbK8RqMhBRS8ecxIsrKHpwEJVsfHx3j+/DlOTk4wHA7x0Ucf4auvvsKDBw+k7I/C4zYYDIrikscyHo/h8Xik+FY/JBZM061hhpj/p/uOsHUHq7KYiNJlYPzRPu5NVIirYguzOwEJciaMelPzBu9SnJPJRNwMv98vylwqldBut+VBa7put9sVP58tGgaDAarVKur1+hRpjNAjWYpnZ2fw+XxIJpO4f/8+vvjiC2xubiIajQKYJoaZ/UHMulGTqM//07xqEoisuCL09ZlNpBU3LZwmE91UC3jVRjSLGHgi6s37S1B04O/K7vV6pbDW4/Egn8/j6OgIDocD6XRaqoSGw6Fg5QCmaLq1Wg1HR0dyVCaTSUQiEbTbbZycnGB3dxePHj1Cp9PBnTt3sLm5id/85je4deuWVMOQkch0tiaccXOZHaEo7BXJU4bHNwCplNIsOt2+Tbe1IxVYf4dehyoEuHE++1XEL/1v4NKds9oYH7I4aZ0JR+nkEZVEw3kMAAnP0bUg+5FFG/T9WZx9fn6OZrOJUCiEjz/+GF988QVu3bqFRCIhi2EiB7D2PWmVrlIyk3qrrbf5Om3x9EPmd2iOt94cN9GqW4m+B/TXeQ9pEMzT6324rrcRpy5P6/f7aDQaEqySHgtAsp66BK7b7QqaYbfbEQ6HEQgExBU6OTlBLpfD+fm5pPaXlpbw2WefTeHowGUwqh+SPpqpsFdxrHUfFf7uuoY6JkqjA1TTwmmcXzcvuunCZ0a6BE9dNp/VRuR9uJ63FTsVi1Xm1WpVcGoAU8kIrZD9fl+SSaxLjUQiQgPudDrI5XI4OTlBpVKBw+HA0tIS7t69K+xFVqFoi6wVSfvHWpGtjlszBf6yU0B/BwPgqyybjgneF0WnkAyns9c0Vhpp+sVYdiZW2Mau3W5jMBjIcafbULMP4Pn5ORqNBgAgmUxOdaIl85F8GRYsf/TRR9ja2nqhYv2fJbRo5sM2N5MJZZqvuQlKYhWIM9ZhMsl0X7Q/fxOu4ecWSSpVq1X4fD7p3AtctlBjXz/SflmF1G63MTs7i0wmIxX59N+r1aqcEnb7RROe9fV1rK6uvlFfkZ9LNC6vxXSj6MNrRblJRRx6PVwjaQIariUVW7/nlyJOBqSVSgWBQEBK2IjQsM85mYNU4n6/D7fbLQ1MWcLH1mqlUkkymbFYDAsLC0KfBW5W5K8zolbHuU5gaTSHG+ImWEWNvvCHbQbJCuXzvM4d/JDFToSl2Wy+0NeaBRuEHUnVbbVa0uI6mUwKH77ZbKJQKODs7EyaYsZiMaytrWF1dVWw9Jsi2n0xFd58ndkqQvvx/2wxC0p05pR5EZL72N2Lr7sJ6/9HiVN3cyU3hF22GGyydbVOGLGulFlPNkjSvRZ9Ph/m5uawtbUlDXlukujAWKNSr2Kpb5KSWCWUmEOgG8OTmt3XgJt1Df8IcbJUi+lz3YWXwQz7AzabTTkO2RaD85bo3rAjGC3/4uIi7ty5g5mZGQmWbhqioS336yj8TRJT4U0CGJmstOy6NcUvRemdAAR7DQaDiMVi0rcRuGQRttttqQYKBoPS9o6oC4NRduBiJVEymZS5R8Tub5qiW/1oMZEXbo6bpCS60ITuiT61WRRPeraZYf0liJNsRr/fj0gkgkgkMsUlZ4BDKDIejyMWiyEej2MyueiUe3p6ikqlIjWZHCXJMjcT6ropVtNU7qsU3Uy1W733ny3mWnTpIPMDnJcFXPLzf0niJLeZu54JB07LoLXm61hy53a7ZRYRG8Az86rrQxOJhDyEq9COf5aYjU2tqK5MvDD5wv+7aZVKWmjV9VhIs1eMucl/CSLKrjvlMiDloCv2V6SbEwgEpMqHCSkWgNhsF41P0+k05ufnEY/H5TNvki9ssv+oIJoKq8VsIHrTLLsWwo66m4AZJ1kl0m7itbxLsetdTyvGfoDsvMsGShwzQ6umR41Q2enqMKvKCqWblpYmn0YPAKaC6P4wFNO/vQnXcJXohk50YUyekN64vxSxA3ghoCFcpZvXs9kRyUV8Dy08a1XZ7i4ej0sb5Jui4Fo0T4TKzo2r2Zf69foaTGz7poiGHHXNqVWnXtOy37RredfiNCtZGLjw3zwGOYkMuDzSgQu0hrDkZDKRWZmc5ABYFxTcFKG7Yjavt0JgrPgzN2kTM5lEo6XdGCsE7Cou0Icqdo3FssLexJtN7gg54jabDbVaTUhhNpsNyWQSy8vLSCQSgqvTP75JikGhi8V7oMe669dYWfabqCRa2WmwKFbrvUmu5c8tdo0umPirw3E5910rO60gezfWajUAkOlqiURCmtmbLSjelbxM0Ux05TohFwjA1KxVVkeZgam2oO9C4d9k41x1bdodZdUXn+EvXZwAJFvKTlmcjuzxeGSStMPhELSCzYQ48LfX603NHKJi60EAJpz3NqIftBVbUfeGMbkvVsJJgBpCbbfbiEQiwvvR6AzRDmae3zZJxvVe9VmmS2XycjSnR7cKYc96Dnmz8tv153/o1t3JiXa8WeYE6lAoJFOq6ep0u13hwbAom1VIsVhMFJvW3SzQeFvRuDgVDpjeBBobt0oaaTydHCC2AeGgBBaNW7XseFcZSL1ejeObUKD5b10iqA2Kbog0GAwQCARk2BvBBatn8EuAHp0ej0ceMtvbceI0R6nrUjT66q1WC41GAw6HQ4ZQkUJA0Ur2rhWeCIougjbjDf19VATg8sGaRdWmC0CUyWazTRU96PpbUiDM633Va9TWmN/N7+C1mJ+lDYnup6Ob0nKQm8fjQSgUQjAYlE1lxmdmr/YPVZxut1t46pxfyhYY7NVINiRbVLBTWKlUkk4CqVRqaiYp8OLxqI/rd2XhNYJ0XbJHt5MAMLUpuC5CkUw2sccl2/7pfiv6vbpK6E1cGt4PrewvC+j1NWqaNptasViD7VH4HgDSNAnAL0bRgb93F2DAaVbwM7mkH36/30cul8Pu7i729vak3UYikRD//h9xHF61cYj9U7Ri0hqaCRW6KzbbxdhKblLSJRqNBiaTi5YjkUhEYhzW0Jqb7Lrr1y4Wv4fF3jrxw3Wb1wtcKq0ukyyVSmg0GkLrCIfDAgWb69EKTteVFO8PWfGdVHLebLoptDLEnNmXpVQq4dmzZ3j8+DFyuZxM1SON4B9xs3SAZrbG02s2IVRzbWYROfnewEXLvPPzc+khz3E7zCEw72D2j3nZRtdIjnYlrPgrFP16HStQ0Qn/tlotxONxcVuIpunNZbpk7D5w03rN/xzi1N272FJ6MplMMR1ttotuAtVqFc+fP8eTJ0+wu7uLer2OhYUFaaFBWrBVWv1dY7ma0gpcKoS29qa15NqINnEmFNfHU67f76PdbiOXy+Ho6AitVkvcNW7Jm1zdAAAgAElEQVRoli/q3phUFisuil43FVsHyTrQpuie6npt/DczvmxByC7KtO66W+9Vz4H+/7tAlW66ODmNghOP6auzey4b+nc6HRQKBezs7ODJkyc4Pj4GcAEvkjNDuSoQfVfQo9XG0ZbyqofHkfP1eh3ValWOfp4GxNhZlcVaWqfTiVQqJT0w2RfH4XCIgukAni31+KfV9eq1MWBk7xu9VmamXS6XtDthP0reZ4IEbHSle+hY1daaKNJ1PXk+JHEClwESrQWPPU6IZnvnUqmEk5MTnJ2dYTAYIBKJCIarlR2YDkoZwL3LLKpV/adJeOImrdfraDQaqNfrQm1gpzLmCWjNqWDNZhO1Wg2dTkcmegOQbgs8+Vi7q90QclHoA/O6rYwAXcTJ5KKxLIvbqdjNZhMulwvBYBDtdhuFQgH1el1a/ZGzFIlEEAgEZBNxPeY4GX0Cviz/8KGJkzeDBdUMckj29/v90hmsVCohn8/LUNzZ2VnMzs4ilUrB5/NN9fjWQRQpA+8KheGRrlEYs2UdcFEXe3p6ir29PRwfH+P8/Bz1el0USSt7r9eT4Wicdk1+/mQywcbGhpQtJpNJgfjY6VhfnxUNWCu7eS2MG+gSaeZpr9dDMBiE3+9Ht9vF2dkZ8vk8er0eQqGQ1CBwDq0VjZdCRdctvK0w/Q9VnH6/H5PJxUTqSqWCarWKWCw2NZadEzYqlYoMGEgkElNDcWmRrJIWOmHyrkRbSe0DU2krlQry+TwODg7w7NkzHB8fI5/Py2wnPQyNwTe5+eY6SXNm6SITNLSKzBTrfIKJuphZT+1KmLkBDaeywzLzIaenpxIvEWlhT59wOCxQI6nY+hlQtPUnGPEujdFNFWcwGMRgMECxWJRZoDwaOUWjWq1K1wBy1ufn57G+vi7T9Dg60iqF/3NUKPEzddPSdruN09NTHBwcYH9/Xyz66empDE7gFBFSeTXCwQdulqyx8avX6xUUJhwOC51CM0R54jAO0IMAdHGIRkd4KmmIlPfL4XAgEokgFArh6OgIp6enePToEU5PT+Hz+dDtdlGv1xGLxRCJRJDJZORHDyzW32X21GQTJfr7H6o4HQ6HHOvsL0JffTKZSEE1j/zRaIRgMIi5uTmhB+huWVZB6btmPOoMIv1bwm+7u7vY3t4WRS+Xy+Ke0B9ns1aKhiZprWkJ2SUtEAjA6/WKMmhMWltxKrZWcs1A1D9WmVyuR/v9TPIBkG5suVwOdrtdgmXWD5+dnSGbzQpS5vV6Jf4id5/Cdf9SxEkYrt/vCyoTDAaFGMUbe3p6KtnUeDwu/jpxXJ0E0T6gVvR3HQjRxTo/PxeU6PHjx9jd3UWpVBJfmtAgNwiVndO79Rq1AvB+sEOCVcJMuylacfVmtBL9e94XPYGasRQ/i9erwYR2u43j42NR9lAohN3dXYRCIWxsbODOnTvIZDKIRqMvgAg6H2EVyH6I4mSLamLt8XgcgUAA4/FYfN9CoYB8Pi+DwhKJBLLZLNLp9AuBqfZZaek1UQt4NxAXR92cn59jb28PP/zwA3766SeZ7tHtdmG328UiUjjWcjwey/h6UmAJ2el1er1ezM/Py0j6q0Rvbv2718kz0M2xGnTAuCcYDCKZTApEyk5s3W4XxWIRw+EQbrdbkCS2HeT9oJ+vY6irklk3WV4nBpRMNSN7v9+PmZkZZLNZ+P1+tFotVKtVCUw5NS+VSiGVSiGTySCVSskAA50UMemnVCA9re1trcjh4SF2d3exs7OD3d1d7O7u4vj4WNptk65MhibjCU78CwQCCIVCiMfjyGazyGazU+xAbqZGoyGzXTVlmTfcJJyZD4Q3+1U2uHkSMGjWgf/MzAxu376NbDYrdORms4nz83Ppwcn6A7vdjvPzc0SjUayvr6Pb7WJxcRGJRELQNqtk1k2X6xCk6+6zs9frwel0IhQKIRaLIRqNinugp941Gg2Mx2PEYjFks1nEYjE5FjUXRSMP+sv178wdaf77ZYrBIO3777/H9vY29vf3pVrK5/MJBMdEUbvdxnA4FAbgwsIC0uk0QqEQkskklpaWsLCwIK0/2G2hXC7j/PxcRtTzWnUnhlfhwlhdo3m9OrilK0TYlpnUyWSCubk5eL1egYrr9TrOzs4wHA6FtcoNr0+vXq8nJ5PD4UA8Hhe3S2+m192gP5dc9/3aKJiv0Z6F+RrnzMyMcCPMahb2YS8UCgJtLS0tYWlpCW63G+12W/xhM21vBl6ad3Fd9pMWycrakK7w9OlTPHz4ELu7uzg/P0etVsNkctm4k3EEg20GeKlUCgsLC7h16xaWlpaQTqelMasZhNrtF8MVUqkU8vk8Tk9PpYMCZ6ZaiUnyMnF3rfyaganvHV0ZKich4clkgrW1NaysrEz1cTw7OxMaw5MnT1AsFnF6eoput4t0Og2n04lSqYTt7W3ZOLx+p9MpuD4zvlyHzr5aXSevz3Qp3naTmOiR6QqTpkygwiyssQIAAMAZDocRjUYxGAxk8Barkjjmkd2+/H4/5ubmMD8/D1KD9UPhl12VndP+sMal9Qaxulmabfm3v/0NDx8+xM7ODs7OzgQXZ5MnJmAATBUxhMNhzM3NYXl5GRsbG1heXsbs7OwUmkTERDeOikajmEwmsuGZZSWn3RSrDKW2UjqusWJumkrjdDrFajscDiwsLAg3nRBpsVgULoxG1jiHNpVKoV6v4+joaIqrP5lMkEqlpq5bKwxgDSpcZVnf1WnAazPjH702DSLo9+lknH4OwN8DVB7LtGjkxjBDyDYZwMXI9mg0Cr/fbxnBayW3unD9kDSHRcN+mh/CpqocLcnkUKFQQKVSkTQ7Z5qm02nxvUlOczgcCAQCgkrMzMxI4kwzPamoJlRKjJ2YNnBx6jGBQ0XTlsjKspv3SP/bZrPJ5+iBbfV6HeVyGZVKBV6vF4PBAA6HYwpG9Hg88Pl8mJmZkc3+6NEjARUqlYpw8dk3n3Dy6uoq1tbWpga5mXDxVajSVTHKuxCr7C9/r3VEv4b1B6VSCfV6XXIpsjFYsKHpubQK1WpV/F1aMgZ2rGQyo/jrlN3MDvK9ZicDSrfbFT7O/v4+Dg8PkcvlUKvVZBQO10Q4lG7W7OwsZmZmEA6HpfCCuLVmcnIT64nP5rq5WRi0djodiQ3oAml37lWQDX286u/Rv2s2myiXy/IcAIjFotUHIL305+bmZC6tx+PB3/72N3S7XTSbTckXVKtVHB8f4+DgAEdHRygWiwiHw1PKbp7IVjHYz6no5nPQJ78Jx+p1sqjo5ORECoumlN3lck0RkJgxLRQKKBQKqNVqsNlsyGQyWFxcRCqVkrrUqy76urSz/n/zosz39Ho9VCoVHB0d4fHjx9jb2xOOOUsCU6kUlpeXxZdlK212G6YPfpVvp90n8+ZR3G43IpGIzJ0i4kE4j6chZxa9bhaSfJXJZDIVVDMJxiknwWAQgUBApntb3dvV1VWJVbxeL/b396UDBDc5B75Vq1WMx2MZE0SOkxXsaRWH6Xv5roNZM1g2YwhTx5gAPTo6ws7ODjqdDuLxuCT0gL/TBZhYIK20XC4jn8+jWCyi2WzC6/VifX0dm5ub0pP9VRZpJbR85uvM9/T7fUEa9vf38eTJE+zt7aFSqUiP90QigbW1Ndy7dw8ff/wxbt26hWQyKZweJk14s6zch1fhg5AewJwEj0jgggXpcDgE7WDsoE8K/UDM62W6nq0GeZqVy2VMJhNxFemCMbmlP5Pu3mAwQCwWw+effy7r+Otf/4qHDx+KK8iCeSq9zWaTiSj37t3D0tLSC0CFvn8mq5Q/PyevxirTa7o4zKIfHh5iZ2dHSkmnKsICgYDcqHa7jUajgVqthmq1ilarJaSvu3fv4u7du4jFYi8sxNzZV8FXVHD6tFbt2ZjhZEXUo0eP8OOPP2J7extnZ2eYTCYIh8NYXFyULOHm5ibW19cxOzs7pQjad9ZHs4bazIekiWz8UxdG8MHTgtPN48nB3+s+ktcpAj+P1rzRaODs7ExmXHEOFWMOU9E1kqX73ywtLaHRaEjjp6OjI+HxkwzHvIHP5xP4ORqNCrntVZRXox7vStnNxCR/d5Xw/jUaDRQKBZyeniISibzAcXLy5mkeNwNTwlHpdBr37t3DnTt3EAqFXrhQfbFWu56/M1l4hPHo/wMXFr1YLGJnZwcPHz7EN998g0ePHmF/fx+9Xk988y+//BKffvoplpeXkc1mkUwmpyySbqVhBltEH0xlNwuyKXb7RaMhrtPj8Uj5G/1qM4egue3ajTLXQSUFINb37OwM9XpdNm8qlZKyR/O04LXo3usAEAgEsLa2Jom0RCKB3d1dDAYDVKtVufelUgm7u7twOp2Yn58XPo0ZP5inoqkD7zIxpe8NxYzptKXXs6Oow3THtJFzMjmhUZd2uy0tJNhnfXZ2VtpPc0FWUbrpR1n9nqKVC7h4cPV6HQcHB/j+++/xf//3f/jxxx+Ry+UwHA6RSCSwubmJTz/9FA8ePMDdu3eRSCQEgTCV9nXiB/N9ev3awlPZOaHE6/VKVwbdW8csLrGyVHygVqgWKcWhUEj4SpoCzFOLm5nIFslodPMACPzITPHOzg7Oz8/R6XQwmUykKKRcLkslFBtjmffJfL4aQn1XYpUUsvLRtfvEoNXv98spzOclys4KHlbc6BbUHo8HyWQSi4uLMiiMYiZOzJ1v+nN8HYUPifECcAHn5fN5PHnyBP/7v/+L77//HoeHhxiNRkin07hz5w6+/vprfPHFF/joo4+QzWZfiMrJMtRwpha9VqvTiHkGKg4DI36H0+mEz+dDLBbD7Oys4LpM8Gj6sLbyOlbhd/Gz2dab95UzkJLJJOLx+NRG1rQHuhu8LgIMDGi9Xi9mZ2eRSCSwvr6OTz/9VHhEz549w9nZmcCak8nkyn6XL4OS36Wim5/NazMTc/r/CMUyl7K6uipwtC51dGpeNx8c3RiPx4Pl5WUsLi5KooaLsPLFr1qsTiBpf1i3kBiNRjg/P8fjx4/x8OFD/PTTT8jlcphMJshkMvj444/x+eef41e/+hU++ugjZDIZS0TCtKa6VlMrt9V6rf5PY+/cuDoQJcedCSz+aAt/3eebySkiM2zb4fP5Xihkvyo+4gajcvAhM6tMzns4HMbCwgJyuRzy+TzOz8/hdDqRTCYtwQOu00repa9ufqbWletOaCp7JBLB8vKydIPg6SSWndaFhdaNRgPlchm1Wg3z8/NYXV3F0tLS1AOxggqvUp6rdr3NZpNOBjbbBRfn2bNn+O///m/89a9/xf7+PiaTCZaXl/HJJ5/gX//1X/Hpp59iY2MDyWTyhcykvnD+ny6YAF6syzTjChNa08c00R2rU0wHp7qIQxdvmOlr80d3EGD+gPRjvcarODn8HkLJeooK0RcOivD7/VhZWRFIslwuT9GEefybz8vqOVu5N28rpnJbxQv6O3nykPA2Ho9xdnY2dUoDgJOW1W63o9Vq4fz8XOgBLNJIp9MvYMcvuzgrK0bl1wXYwEVQenp6isePH+O7777D8+fP0e12MTs7i3v37uFXv/oVvvzyS2xsbAhaQN/UTIDwO61875cdt+YG0rAllZhr1pG+1Qbga3QRhw6YiUBx/YRTgctqfyv40grO1BQFsxZXu3V0bbxeL6LRKNLptExCJDJmZmf1NZrCa37XAaqVJTefiZULarfbkUgksLi4iOFwiGq1Om2UiAlPJhNJITM1HYvFkEgkplyY112wuViiMJPJBMFgEOPxGKenp/jhhx/w3Xff4cmTJ6jVaohGo7hz5w6++uorPHjwAKurqwiHw1OlfzabzbLwWm8A+rX6eDet1FV/cr36d7TerHU1Owho4e9IrtIPySpLSTSBySr9OqtTjPiyzkibr9HBr5mx5akeDoclMUZs/2WnNuWqrPPbCK8XuISCTUOpnyPh6kajAQBSn2DeDyetQK/XEy6Fw3HZv1E3KuUHW+GqVsjLVTdAB7eDwQC5XA5Pnz7FwcGBFBJvbm7is88+w2effYbbt28jkUjAbrcLxZbt57TFNNfxKtbGXKNVxK+vl+4e8xIcomuFCesN/yoUAjZuGg6HU9CZlTuoGZLmcW3eg6sgQ9433kvzvVYxwnX37l0KT2ddGMQ1md/b7/eFim6FxAldgBm1SqWCg4MDVCoVLC8vY35+Htls9oUUu/Z/9e+15brOj7PZbFN4ONvMHR4eSo+W9fV1/P73v8cXX3yBjY0NxGKxS79LBbVaEfRDMq3xdTfUSng95uew3QV9d7oNmrilffyr3Bu9Tr6GQTp70BCf10rIE20yuew1o10hnnRsWso1W7XMoFtjggf8uxnYv2yzWjE431Y0jGrlVjEoZ6Y9n8/LvWq32y+4r04GpcViEYVCQdq6scDBykfkm83jxrT45kXz/7X/X6vVcHZ2hkKhAJ/Phzt37uDBgwf43e9+h1u3bmFmZmYqSKNPan6HtsIv882vshJaUYHL4I6IicvlgtfrFd7KZDIRRqR+vz5qr1J0bSBcLtcUHVnPpKWS6dPQfK/po2u3zsq31cE438PTQbsL5nO+TonNU/BdyMueKeHSVquFfD6PXC4n/CTSOfg64O/KXigUcHR0hH6/LwUO8/PzMpFCfzEVT6eprXxhK0XXN2I8Hk8x8HiifPbZZ9ja2hLXxYpVqY/16/xtikkPpeigzmazveAidTodKYyYn58XekC9XsfJyYn4uS6XS5ATcoysFJ1jX7QvPxgMhJ5BghYZiizw1rAirad+LrR+pgW2UnTTxdJBpn6fWYv7MgV+lQ3xusJrMdExUwaDgfQJYtNZxmn62pzj8Ri1Wg3FYhE+nw/z8/NYXFxEOp1GOBwWq6ERFI1Q6CDqVfxS3pBut4uTkxM8f/5c6Ji3b9/Gv//7v2NxcXGq1bL5kPRn6d9Z3eirHpi2wtoF0M1c2dyUHQbsdrsQtXZ2dqRwxG63Y2ZmRtZsWjkqJDujeTwe2Gy2KT5HpVKRyi9Sdgn3mpU3dHP4oE1G4nWnsVXMZd6bV1FuU97kPS+Tq7Km5lonk4tkWqvVQjQaFV4S3U2Kk34h+5Mwa6eHD1hdGC2JyUYzF6YXrRWhVqthe3sb29vbcLvduHv3Lm7fvi2b7LoL1Ou4ympbfT9wiQaNx5dNgfg+tnKm1SR8xX45o9EIJycnODg4wNOnT9Fut4WCTHoxi0IIj+q1cr2s6SXMSxSBXRsymQzi8bisg3CgtlQ6gUS3zrR6VkbAvEf882Wgwj9SrgJBrosTWcBiUi+0XjiJvZJVR4KTqejal9NWxMwS6sVoN0crW6fTQT6fl2ZGS0tLuHfvHtbX16UrgA6UzM8w18OaTfPIJrSm38cgkGzLq/Bks+oll8tJTS5/2Ldld3cXGxsbuH37NlZXV5HNZsWyUFjqx2s/OTnB3t4eyuWy8FiY4WSHNS2mX84uXiSAWfm2ps9uZSWvMgr/TOFztcLadfxGZXc4HNKWkK4hIWrgcpPIHeQbEokEIpGIJcVT77ir0srm603p9Xo4Pj7G06dPsb+/j2q1ivv37+POnTuYnZ2d4onozWXCajqI1DOVdECnayu1/0crqWFXHoOtVgvj8RjtdhuPHz/Gzs4OGo2GlMQ1Go2p/pB0A/f29iTAHI/H4jsSLiUOnM/npQilWq0CAFKplARVp6enqFarU4zJYDAoFVf6Yev7YPWsrhN9ErwqevWPkpcBDfqaGb8EAoGpjtOcGKNf79SWmV1qQ6HQtdXz+ov0h5kLtpJGo4GnT5/i0aNHKBaL4u8uLS1NjXjRF32Vn64tO2MGDUdqVAK4hOF0wTJbU7M3TrlcFk7/s2fP8PTpUwwGA0mj05LQ72a5X6VSkRtMNCUSicDj8aDdbqNcLktnhO3tbVSrVfj9fqn8CofDaDabePr0qWwkVkil02ksLCxIoya6SKbr8iZ+tlasd5kF/blFW3kqu9frxdnZmbiFLJYXZddt0PTMoOu4CC8TfXxoYL/VauH4+BiPHj3C3t4efD4f5ubmpDETv8f8DNPS68/mpjRPGqujWwutKHtYkv1Jy12r1aQXOtmMhAO1n0zrwd45ZD2Ox5f97Z3Oi6mDGiXQww8ajQaq1epUphXAVK9IzmUl3ZfkrldJ61/ny2s05qZYdo0UAS+WBer1k3JNhmOlUsHx8bFY+qlKJUbzwOUYQauehqbyWP0/MK2QemHdbhe5XA47OztS+X7//n188cUXyGazUjWvP0MrFX9vBlW65tMMZsyNwHWNx2OUSiX8+OOP2NnZQbPZFB+PisgKJACSuOh0OoKS0DXSjY10zxmeNGRF6o4NlUoFwKX7dH5+LqdHMBicqopi3Su79iaTSaTTaSmuftlRr5+Hfo7635rReRPE3Hxk5GrjCVxeC1moDocD5XIZ+/v7SKVSSKfTUzGlkxfp8XgQDAalNZwVjGj6zlZ+lXYr9E1lMHd4eCjFvysrK9ja2kIikZhSGn6X/lOvgQqpA2X9/XqzcR2sr6UFz+Vy2N/fl24FrMqim6DZoFRS4CI1zRYahCJpMEajEUqlEk5PTxGLxRAOh8WQFAoFnJycyDAHTvtgfMDEEmsKxuOxdHIgF2cyueijTwXgwDC2z2acZXWime6heX9f5+T+R4jpuupknykul0t60rMDBP33qYJru/2yIobt7/QwMHMBtAJXVQNdtbBGo4GDgwOcnp7C6/UimUxiY2MDKysrsNlsUvBgRdQyv58UB7peeq2MxLVfzd+zd/vz58+Rz+eFRNXtdtFoNCQ5RHeDKBVbd5C74vf7JfLn75lcYvELlSscDqPf7+Po6Ajff/89Dg4OUC6XZXNxJOV4PEa5XMZgMEAwGEQqlRI4M5FIwOPxSPU8uz/4fD7Mzs4im80ilUrJpG6duDKRMP553X2+aWLqmCl2u10qlGjhaRCZKAT+rux+v39qNs+rDAMzCUhWrgaFWcJCoSDU3fX1dSwsLEj9JduZ6Qu86sKv+i79d51cocU9OjqSJqjslmWz2cSS8vOYWdWFGNpCkLtOKixnxHLTcuIH3cLhcIizszPpR0mloyVnC21uHEKjzHtwkmEkEpFNwi4LuVxOyus0Lg9cwpU8DW+6UmvR6zXBB1Psdrv0DkqlUlKPTG6NuDEacozH41MsR41zW1lvuh0mHq/dHSZmKpWKFMLeu3cPW1tbSCaT8j5dHGK1wfTv6Kdp+JCv0YXOwIVCEe7b3d0VN4p9G3lduscMj0K2FKnVagAgypdMJpFIJBAIBMQqc3OwoVGhUIDNZhNr0+/3BY6k/84ZT8wA8hoHgwHq9TqeP3+Oer2O4+NjLC8vY2FhAWtra7hz5w5qtRpOTk7www8/IJ/PyxQQm+2yptXs624S1CgaYbsJG8JEiOhOAtNUceDSqAUCAaRSKayurqJYLEoNtSa0OW02m0StOkXND7wqqWMVGHE3auVnv8h6vS7U4Vu3bmF9ff3KQQbm51klS7SS64hbB8Wj0QjFYhH7+/t4/vw5jo6OUCqV5BShG8NCCvrRbGvR6/XgcDgk2cYTkApszhjVNZzcMEwA0XDQOJDART+81+sJqYzXXK/XhYvDz2LL8Gg0Co/Hg1wuJ0gQkTWzuknfN/2n+eyu+r9/tOjnbeZZzP/X1xgOhzE/P49isYizs7MXdNYJQPp564QOP0hDPhQqGxWVi9IICq1VpVLB2dmZ9HZny+twOCydDDgljp9tXox5I4DLiJ0KS0vG9RPFeP78OR49eoSDgwPx04mDs8Vzq9WSZp8ka9EFYXvueDwOh8MhfBa2vNAVPvx+9p0kV4b3IZ/Po9PpyOZiSw4OZiNM6fV6pZMDu6IxB9DtdrG1tYWNjQ3Mzc3hX//1X1GpVKZadZhtO15FsW6Sm8Nna8Vnp1idRmwZMj8/L4CEvg/OyWQy1VDzKuWyWpDpFzNIs9svR01WKhXpcU7IjGxGVtqwbtIU03XhReoLZxBiTsUgM3F/f1/6t7MWk5/DjrccB9lutzEeX/Q0j0Qi0kaEjVBHoxHy+bxkUNlcSrtTzHZyooe2tnR5ut2uYPD0s3ka6Aw17yO7XTHRBFz0hVldXcX8/Dzm5+elSN7k+/A+XmUNb4qCm6JPZ65Xu9EUM06jS866Wp09dwIQyIoK+DKaKD9Y3ygyBukzEyOuVqs4OzuD2+3G5uYmVlZWJIGkm+PrU8LqQehgxerGmLBotVrF4eEhTk5OUK/XhUfCIQNsSET/fTweywgddrZluRprczmcga0qVlZWpHkR10d6MJv2MFG3trYGl8uFer2Ow8NDnJ+fS5+W4XCIQCAgwEClUpEklEbKnE4nms0mdnZ2JOje2toSlqSOV/S9sGJNarkp+LopDDCtXFbzmVPoItIl1DUBTr5Bp9kp3ABW/rr5b31TAYjfS4SBLZXT6bS816oS52UWx/xe+vt8wKPRSApCjo+PUSqVpgoTOHCMgSd7zNMizM3NYX19HWtraxiPxzg/P8fp6SmOj49RrVYl+bOysoLFxUXMzc3JZAtaeip6p9ORnvHsttXv97Gzs4PHjx/jhx9+kF6axMntdrtkVVkYzQQJOfaNRkMoxoFAALdv35Ysoil0RXVAd5Uvf9PE6kTSenIdHMkKshe6CxCTtLoJVr6fhueoZAzWJpOJNEctFAoYjUaCA0cikanPMhGe6y7a/LdmvOlqHTZZ2t7exunpqSgnE0mnp6fSS7HdbiMQCODOnTu4deuWsD0DgYAMTtvb25NBx8TXU6kUFhcXxa/mZA6SuEgmY7KjVCqh2WxiPB4jnU7jk08+kbbaT58+lVNDdwgDgE6ng5OTE2lXzQZAbrdbGlv98MMPqFarQo82hdlH4LKkUbtyWpmsuPD/TCHEq6FTKy/D1Fm6i7qrA/B3Zdd4pAkjmjWoFL6eO4xHKFvpsb+7w+HA4uIiZmZmLC3Pyyy5VaDK9QKYaooKQJI3R0dHYjUZjN+pQA4AACAASURBVJ6engrTkgmseDyOra0tfPHFF3A4HGg0GgId7uzsYHt7GzabTTg8nD5H2JQFKE+ePMHz588lNpiZmcHi4iJ8Pp+4Kxy/+dFHH+HevXvIZrOYm5vDN998I22WHQ6HjGk/Pj6W4N5ut8tU8VgshrOzM0GaCoUC3G63oETaFeW90jEWlcds03fTBv5ql9g8mV7G1OR1T+HsJvrxKkeaDqDMQIgEJ8JsZO5dx6R8HeEO1xxuNmU9Pz/H8+fPJUNps9mEmHV+fi7+MeHEzc1NbGxsIJvNot1uixvEnoHkitOX5zxU/r7ZbOLw8BCPHj0SRWftYyaTwf379xEKhaT6iS4KSV3pdBqtVgtHR0fI5/Pio6fTacnQslyPpXucbLi8vIxoNIpnz56hXq/jyZMnaLfbWFhYQDablThCIzP6eTGmGo0uOxLfJKt+nbyq22UaStG+V3En+Dqd1DGDVB4dTFZRcXgc6YW8qa/IzUbosV6vY3t7Gzs7OygUCoLO2O12VCoVGefe7/eFaLW0tIT/+I//wPr6Og4PD6cyniRi1et1FAoF6ZmYTCaFE0MWJ4swOGITgFAhHjx4gHg8LqcdGZRnZ2eSCCFuT3pzJBLB6uqqzJjtdDo4Pj5Gu92WYD+dTmNlZQXZbBZ2ux17e3s4OTnB6empQLmEMBmwmcEc0Sgq+7swRP8oeZmOUkz9eqsrNCFAEm+Yug4Gg0Iws6KjvqnwBNHZXWYUm82mBK4skD46OkKtVoPH40E6ncby8jJWVlaQTCbR7/dlnmg0GpVuxQ6HA61WC4eHh4KHk3/C6xmNRjKJT5fGUUEfPnwo/expVcnFYasHts7wer0YjUbyXUR6gsEgdnd3sbe3BwB49uwZ3G43otEostksVlZWEAwGcXx8jHq9jn6/j/39fTSbzanySpM9qoN2AC+4sB+SCM7+um+0ssj0/8j+48MjxZWjUayypG+ycCoMmYGsPNJj6RmktFotmXi9tLSElZUV/P73v0cmk0Eul8PBwQFqtRrcbjfm5uawubkpLMxKpSLt9hicZrNZGaDmdruxuroqljqfz6Ner6PVauH777/H8fGxNPifm5vD2toa0um0KDkpCZyzSh+aBK/19XWsr6/j6dOn+Oabb/D06VM8e/YMzWZTal05R+rWrVvI5/PY39+Xcr/5+XlkMhnMzMxMKToNEnMbPCHN+OdDk9e+Mh0oWAWX9NNNvPNVM3qvKmbPk3A4jGw2K73SmTI+OTnBYDBAPB7H5uYm7ty5g0Qigclkgnw+j3w+j0QigeXli5GRHL1IpMbtdov173a7cDqdknRyu9347LPP4HA4kMlkZCBXs9mUBBtPtlgsJojUeDxGo9GQTgXFYlFGP5JmTCiRLTp4krHp7PPnz4UxOTMzA5fLJVnbVqs1BWUyCNXQsJkQvEkZ1J9LXkvZacGBF0lD2jckvskEi1b0t7HqfL8+9rvdrqAfH3/8MYrFIo6Pj7G9vY2//vWvqFQqCIVC2Nrawu9+9zvMz88LDr+3t4fxeIwHDx7gt7/9Lebn5xEIBABApujZbJctNei7AxAl9vl8WFpawtOnT4U6zA2nM3qZTEYmaXAEO0c0npyc4Pz8HJlMRvxtPTU8Ho/j7t27GI8veu0QAWo2mygUClhcXJSJ48zccr6tx+OZKkDWz0Xfz/+v7NeIqbTkptBaaK6Ifs+7uKn000ejkRClJpOJZEhZQJHP5+H1enH79m1pd22324UrY7fbMT8/j/X1dayuroqi03/1+/1IJBKSMMrn8zg8PITD4RBEhejJZDIRq6onmWiuNbOxbB7L8r9Op4NgMIjZ2VksLy8jmUxOuRMulwvJZBLZbBazs7MoFos4ODjA3t4ezs7OsLx8OWqHAThdSLbVuwpxu+m0gXcpr63sZkQPXCofLQR/Zyq6WR72psIHR85IoVAQeu2jR4/w7bff4uDgAA6HAxsbG/i3f/s3bG1tIRwO4+joCD/99BPK5TL+5V/+BV999RU2NzdF0XldDocD8Xgcq6urACCN+weDAQ4ODiRgzWQyiMVicDgcmJubk+KBQqEgWVda8EqlIpOm6d/bbDZBV+7fv4+trS2kUilZD6+VqAkLOY6OjqSHze7uLtLpNDKZDNLpNGZnZ4XFykZXvP/mc/klyWspO5XaxC95FF51I7VVeVvRASqb6ZdKJYHlHj16hJ2dHQyHQ6yuruLjjz/GnTt3JBHz/PlzVKtVeDwebGxs4N69e1MDb/kdbrcbqVQK6+vrglUXCgUhXJXLZelEMDMzIwW+Npttqm3dYDAQl4VUBvKt7XY7YrEY1tfXcffuXWxubkptKZMhpB/wtKBRYXVVIBBAq9VCpVIRl4vVVIlEQuanMmDXKXeNuetr/1DltS07FVqn7K8ih5mb4m2hLX53r9eTwgrOBGK284cffsDZ2Rlu3bqFr7/+GltbW4hGozg5OcEf//hHnJ2dIRaLSbCayWSEe05/WecIQqEQUqkUZmdncXh4KPQBm82GVqs1heETiiTbUVcekSs/Go0QCAQwOzuLlZUVLC8vY3Z2VoJXAMLEZN6ClOJCoYBisSiDIhYWFvDRRx9heXkZPp8Pk8lEJg263W7EYjFhV+qmVqQP6Hpbnmav0sLwfZU3Unb9dx3pX+f/XUXRfBOhxaQC0cqzP3cikcCtW7fw+eefy3SJvb09fP/99+j1evj1r3+NtbU14bawTwyDOp5eRDSYbOLEunw+L5aXBdPsPqCTOZrLwSwlk2ycKrK0tCQnwXA4RKFQQLVaFT4OM8Tk8thsNpkaOBqNcO/ePSwuLsp1AEC5XIbNZpPAVBeyA5fup7by7+rkvcnyxgGqplha8Vf4GpOL/DYiaV+nE/F4HOPxRSs9l8uFaDQqI92DwSDW19eRTCZRr9fF6rMskJAi/WeOh08mk0LgoiIzb0BLysJnuhh6yqBWItav6lwDk2xEk8LhsDRQYmDLob/5fF42HGsNwuGwnAi3b9/GZDJBNpuVwLjZbGJ+fh52u11GQbJuldQBkvY0FEkE7UN2YYC3TCppn8+0Dj9XlE/4LBwOw2azoV6vo16vAwBmZ2cRi8UkrT8ajZDL5XB4eIhyuSwJHnbpOjg4wNnZmQzBZfkbefYsSCGk53Q6pR8jcDlynllQugSEFjmGhi1K4vG4tLnje0maYzuPTqeDXC6H8/Nz2O2XY9xJPltZWZlq0cGxN6y6CoVCiEQisqG5HkKhRMmYXBqPrXtefojy2ji72QCJlv1lR6HG6K/jIb/KGvin2+3G7OysJIFGo5E0Bm00Gjg5OZEJcplMBisrK6Icz549kxQ8rTLbb9AKM83O9ZL+y4ouWn7+sGqKQSXZhs1mU1r9sVKJP+wuwBYaVFCn04lAICCtAdfW1qREUI+24fcRYtQ8b+2D6/vPZ8c/dc+e/++zK3lZBvUqMWmZbws90iLNzMwgk8nIA6NV1vWL0WgUsVgMmUwGg8FAKpjY74UKzeKLQCAgFUjE7judDtxuN+LxuLRp4PFvt9ulUJvldZoeTYZhu91Gp9OZcnv4w0SP3++X2CAWi2FxcVE6BJNnQ9EbjVnqVqslSI/uR6n53RoqZqxgVWv8ockb4+ymsr5MeTXr7nWUXfv95r/1htNWiQ+P1jEWi01BeYQHaSG5Lk7jI7TJ7gL66GfXAW3JWcTicDjE0tJl0J9PLgo3A2kBnJpNCjFdKfLTrfgq7FJGjhCrnazam5j33xRdjWaFxVu5qC97fm+SPPy5s7ivjbNfRxS6bqEve+/LvvdVv4cjG/v9PjweD2KxGCaTCRqNhow6Z8Mhtg6hO0KFJq+GbEj2iyFFgYUj/X4fpVIJvV4P8XgckUhEfGHgMqvMTmOk8TLjSy4L60+5+TgAgb8DINRdr9eLfr8vNazk55NH4/F4ZAOZRkLXAGj0TLtlr1LN/7LncBVg8Srycyr8e0lxo/+pLbw+NQjvJRIJKXim+6BdDPrk2i1i8TOD3/F4jEgkIr3jGez1+32xrKwiSqVSAhNqyiytPBtwMtnDXo7RaFSQGm62crksLTXYy5EFKizm6PV6UwxTku5MSq8Wnoy8j3ozMKa46n1Wf/Jz3ofE1Hur7Bo/1p2v6BLQmmoXhg+X7g6TPPpY7na7YhlZ+8mqIo/Hg16vJwrPBq2dTgdLS0tIpVIoFosAIGvTLUZYckdIkGtNJBLCZyGDMxaLScE1u5Sdn59jZ2cH9XpdelJycgo5MVbku5fdS947K5/dTAhe9Zm8v28DPvzc8l4qO4Apq2neXE1K0+Qz+rK6yomBIk8K+tV+v198byqTzXZR5keUpdfrSdKKylqr1eQ7AoHA1KnB9tXhcFg6jNHtGI/HMt3aZrOJ26QpxnTFSHojxEhF11Tqt4USrdC166ggN1XBtbyXyq4TI1ZkM11ErN0c091hQQndG34eSV4sZtAZW6IvdDuAiy4A5XIZp6enYvVJs9WdhDUyAkAKQMi1OT4+RqPRwNLSEjY2NuByuSQ7XCwW0Wq1BJ7kDCY9fuZNchtWwaZVZvVl7ovOFt9UeS+VHbBmVer/M19nFodTGEBSmbVPT8vLomt2KmD9KMXr9eL8/ByFQgHtdhter1fasAUCAfGF6XqxfI4uEwcU5HI5dLtdpFIpoSGwvw37smsabzAYnGrQ9CryOlbYyhfX/7baCDeZdvDeKvtVom+8aY20tdJHPRM5LGpmRpVJHVpRt9v9Qps94KJ5697eHp48eSIuCEvlmOkdjS6m9J2enuLJkyeoVCpSUkglYXkeK5kqlQr29vakXV4ymcTc3JxkcF8F/uOf1yFaVjx3/lvTPa6CIG+yNdfyQSq7lZLrBI5MYvi7X282Wup2u0LfpQUeDocy+oUPnP9H6nChUMDs7Czm5uawsLCAVCo11cOSmd3BYCB8d5fLhUgkIjSEcDgMl8uFYrEoIyjJvoxEIjJEDLgsp9PXzuulXIW8WImVj65PQyvLftUGuYnyQSi7lWUyFV23k9akLRKsPB6PcE5Y/c9WGSydo28MQHqsk7TFFsnpdFp60ZinAJWWCnt6eiq9DOfn52U8ZrFYlPYcLDlk8bSeOK7hV51Iug4KvMo/12JlMK665++TvPfK/jLEgGlyWmFCh7rlB3DRFZfNTckUJLpSr9dlIIH2v9k8tVqtSncC9rMkEsMfKmIwGEQ2m5WAVncCZpE1mzqxXI892em+8Lqsrv86Qp6Vopt/8jVXoTnXcaBu+gZ475X9OstDpeRUOnJT2IedD7fRaAgEyA5msVhMCFzn5+fCjuRm4QBgWufl5WUsLi5K/Sj5MMy4MqEUCARw69YtOJ1OmTNls9lQLBaxvb0tp0ipVJJmS3Nzc1MTUYDL7gDap77OGr9KtpM/1/FjzC66OiPLTX1TGZTvvbJfJyaEpq0SHxCnzgGXozFpRXUnM54GwGWHYvr05NdzyAJwSdLSA6wYF0SjUayuruLk5EQ2YaFQQKvVEjoAiWBLS0tIJpMvKNBVCvVzBIs61iG3yCyo15vgpsp7q+wvc18YXLEogUkdTcHlMF8O+iXeXalUkEgkZFhAJpNBKpUSJecso36/LwPXmPInmgJA0vZWKXieIKQylEolbG9vYzgcYmlpCVtbW0in0wiHwzLxw2Z7scjiTTOXV7k6+k/SMhjDMNYhwY73mFZeF9TfRHlvlR14ucLzSGVQR8vOOkyOmAEumIjNZlN6MlarVUnbz8zMYHZ2Vvz7SCQiRCwWNDPo5EPnBtNrZa0n3Q9O6eA0D9KO5+bmZIOZ0wStOOq8D69Kz71K0c1AXxe204Wz2WzSQYE5ivcFgnyvld0qGDX//7oEE7tvEXrk7+jjc0pGOBxGOp1GMplEJBKRYmiSudiTkQrA0jtNBqMy8Xfk2adSKRweHgqSEwgEsL6+jkwmIxQFAFOcdPrVvBZet1kHbBW8vuz+6NcwN1CtViWYZpUY6clWc1ev+rzXfZ5vKlcF0e+tslspulV62+q1wCX/nX40eSuhUEiKt0ulEnK5HCaTi+66MzMzmJubk9GN9KvZ50Vj9jabbUox9fpIPmNbPAbHy8vLmJ+fx61bt6Q/DK+HiS8OLNPug9kSwwoPt0rtX3dfGctwqESxWJSJfsw461OFp44Vxv+qclVy603E6jPeW2U3xbRor3KsMohknShZiJyOx3GRTNd3u10Ui0WZZ0RKAauXqHQs8dMwpUYqqKj8O1EavSnM9Vu5KmZG+FUyqlZQpG6lQTes3W5jf38fT548QafTkTmrqVQK8XhcWJk6UNafr102q81otVa20ebrrO4X369Jfvr561PavHcflLK/jkVgLSjbRPOH4xw5nsblciGXy6FQKKBUKuH4+Fj6QJIsRtSGkKOu5xwOh/J68mz4sGgZSRqr1+sol8vSRYwnAIApRAeYzgpbXf9VmDrw4ngfXZYHXKBNpVIJOzs7+PbbbxEIBLC1tYXFxUWsrq4K3m8iW9q94ueaya7rnlG73ZaW4/rkpbukRW8q4HKaN11JqwZQH4yyv4nowmOK5svMzMxIIXQsFsPJyQkmk4kMMPb5fFKfyodiWhWTb0/RaJHf70cgEBD6ri7Y1q/XCm1adBP31t/3sgBSW0xOBN/f35d2HsFgEDMzM0ilUgiFQvI+s6c7Nzr/bvLqtXUGLmgZzWYT1WpV6MucXUV2J2MVDTRYnXj6+/VoGf3aX6yysyBZZzd17SpdlKWlJczMzKDZbCKTySAQ+H/tXdtPW9fTXceB1GADNgSsCAytCg9t0+YpT/3TK/WlKlIbpaUVDSlFiVNiLjY33zC1sf17IGuyzmQfh0Ck70tgpCiJ7WPvy+zZM2tuGVQqFasvw+bCTKbwOaOU/KHQY3U0sa0NVSumEOr3kJShvRNHjeAkSe/VCdbJAS4YcHt7GxsbG2i1Wta0TBum9ft969rNMGkeNG0s52FSz+gsFPvs2TNUKhUrB86aldoMWm/EYQ4yjWXyc7+xzA4gJg3pNNHCSEzcSKfTGB8fx9nZGV69emU1F2mQEZlhEBfDhFV391JXk0IYqsu0P5bOo6QLOZCSjDlvjPr5cq6ecVKplBmk5XIZ5XLZejcVi0XzOyiEOgzd4e/wdc6h1+tZ2W02XXv58iXa7bYxOLuN8xkaw/4mSZq/dshTutHMTmJXNa+DqnrDfzNUIJvNWpkNBpGx9SWbCFNq+u7dVD+0rJ5KdmL+p6enVvcmiUJ6sDdc/XsKUXJe/f6b2u87Ozs4Pj42Dy6rEwNx+Jb/59+qalDC8jcYytxoNPD3339jbW0Nq6ur2N7eRiqVMkRrbm7O7Cb9flJIFfTvJalsN5rZQ0ZeKLZDHVGs+UKpzFJ4qpvzmSQJq0QGYS4pvZSs/0K4b5h0v+rc+XcUXYRDVCoVbG9vo16vWzbU/fv3MT09HTtwequpBNUbTG8MABZMt7W1hSdPnmBtbQ1//PEHzs7OsLy8jGKxaL1h0+m0qXk0TodVLfMHLknVubHMTkOQVyOt/ZBUYGJHo9GwjnfK7F6/Vt07lC6n+i0RIY4hnU5jMBiYd7fdblti9WXRpmEGqTfIicI0m028evUKpVIJALC0tGRxOaxHo6rP6OioxcoMBgNjSM47iiILie73+3jx4gVWV1fx5MkT/Pnnn9bMeGFhAY8ePcL333+PhYUFTE5OGqxIQUDdPakUix4uj8Yo3VhmB95IX0qqJNIwYbZ/YaIz8Ea1IXGxFXf3agWNKUZGkjkGg0GsOjH/TaNZKaSivMuIU+mrcf4nJydWApw1Jefn52PdSPibqspQP9aQDFY4S6VS1gnl2bNn+Omnn/D48WOUSiX0ej0rSfjdd9/h4cOHMUbXqg+aWONRFq1Qx9dvJXuACI2F1BZFaVTVIMJAw1LLZShxwdkEmYyoDMuKYtxYlgBhjirDk33Zaa+remPM4+henfIHjozOzt8zMzNYXl5GoVCI4fwc/7swfJWs1WoVa2tr+Pnnn/Hrr79ao4i5uTk8ePAAjx49sorLRIU8fKqYOdEeBQcAJEp9pRvL7Nw4b8R5PZ6Shs9QwhJmpD5NvJ1NAVQChiITCS+2Wi3LVmLFBEp8Gs7aE0l14RAje6mmerU/BBwDGx10Oh2MjY3Fyl1zrPwNXx7PG6p6c9AYXV1dxePHj/H8+XODBGdnZ/H111/jm2++QaFQMJtgWCy8wrc6D09JtsyNZXb1+nkp6F8nI1NC07OXTqcxMTFhCSEHBwfWVIw3ACuBAXF9ud/vW9zJYDCw0nZkklqtNjTex/8/CYEhU3umpM3CCgYHBwdWFZklv3lQaSxSnaOPgXaG3oL8jf39ffz111/48ccf8cMPP2Bzc9M6gOdyOczNzVnreXYHDKFOerj0QOmh8vuaBAzcWGYH4jAcN1bxY0rETqdjLWOAN+U3CB0SNalWq+j1esjlcjGjMrSJrVbLytwxrj2bzaLf79sB8AnVIeLYvRqlc0w6BJ1Ox7Kxjo+PMT4+buiLbx1J45PMztdC6sP5+TlKpRJ++eUXrK6u4rfffjOJznDoe/fuWc35kZGRWMMEEvdDhYSqll6d0z29ZXZHaszw316SMjiJRU7ZSYNRktls1kpvVKtVY4Z8Ph/sZjEYDHB4eGiOm9PTUwusymaz6HQ65pgiA4c21RPHHpL+IWSGsUEs2dFsNq39JAuwhlQWoiv0S/g28WdnZyiXy1hfX8fvv/+OUqlkjK7ZTaOjo9Y4gsLA14n3hzSE73uj3d+GSjeW2ZUJkmA6Stdut2vwIh0kLJo0MTGBiYkJnJycWHVeDfVlogOp2Wxid3cX5XLZSuUx0ymTyVhtderrOlY/Nr73rs+E0Akyu5bVY3EnLRniD5lWV/BIFm+lf/75B+vr69jY2MDBwYGpG2RiNnyYnJyMtcDU1MfQ4Q7NMaTK3Ur2AHkHCKWpz69UI48bxqv83r179pmDgwOcnZ3h+PgY3W4XtVrNkkN4S9TrdSuHfe/ePdNfGVND1UdzV3WT/WYOQ0c8s+vnmJLIHFjq0wy+0jAHqi9UJ4YhH6y4UCqVsLOzg0ajYYhVp9PB3bt3sbS0hC+++CIWVKaAgR5OP3d/e6nxHYo/Ur3+RjO7nn4abPRYaoSdLjzRGMKFzEElgkImYgVgVY8IQ7bbbWQyGXz++eeYn5+PFT7S2pIhnV1jeDi2pBj3EO7O24o4PoOmVDemLq7IEZPAte2OlvPg/w8ODlAqlbC7u2u9rpQ50+k0VlZWsLKyEishCCB2wDy6k7Rnntl5E4ek+41mdl1EZWglMr1Kfa+Ls0HwYDCwJA86hLwUZjhvLpdDoVCwpmIk3Vzqxj4jCEhOPVMG9ckT3gFDyZ5KpUytYIMGVSM8k+t3cIyjo6Oo1WoolUp4+vQp9vf37XkdJ1Mc5+bmkE6n3xp/yO5QelciSLPZtCbQWpIcuGX22P/JyCopuZhUKyj5vGE0PT1t4QP8w0AuSlfmp9KwVYmuRAalhNcgNQ+5JTE8bxKOl//nOFixgDcZGx8wmM2vS0gVojTngTw6OsLW1haePn2Ko6MjjI2NWYVk4KJqMftbMTNMmVvRF5Jnas4tZI9EUWRqIhu2MVEduOHM7onGVlIYqerL3jBjyK4apux3xO/W+BcyvSeqEjx0ISmn0tpL+mEhsIpm8NoHYHE+DMDy5H0PHKN+H+N8jo6OsL+/j0ajYYYucHH75XI5g2WBC/g1lUrZXIcFcYXG5OdINIiChjE9tzp7gLx+S6I0jKLI3Ph6jbM1I5l0cnLSMHN+r4+u9IysEo6OKGUCz7Qed9Y8Um264O0N/R6Ol/2Yoigyb64SGZmHiQ4ljoM2DG8i+iP0sBPpyeVyuHPnDs7OznB4eGi9onjbhdLvkpjfS3juBdUXHlCO4ZbZX1PImCORUVKplBl2SV5NvqZXLhndqyMaQOWNstHRUQuACknrJKPUf8Yb2EpkAnqDqVYAb6IhdUx6c/BzhEj5e8y8Ojk5icXsRFFk/gmiWd1u19SskDp3GdJ5E6dXO0eFzC2zI2zshCRtFEUG1SksqKoPJQuNVG1jY4v+enMZW8PwWJIiIknM7klVimEHV+dMe4DqFSV/r9ezgkicW0jFoRTvdrsWe14oFLC0tIRut2sFqABYyILeOrQVuAbDxqrz5txUcuvtwmdumT1AIWZXQ4mSFoA1/w0lQyusx5LXGrVIaUlD9b///rOOeb5qgOrHScyt4/ceVH+zeOnOsWrObVIlAD04IcOYh4I5uw8fPkQ6ncbe3h5OT08xMjKC+/fvY3l5GYuLi5iZmTHIVpl9WJh1aEw6R77GtQ1VKrtl9tekC+ZVAtXZ2+22BS6RlJm82sI2ktT16UkcHR21+olaf4XXsEdhhlGSmsKx6Y3iD4mqVWr4qiRnyITeGFqfhYFhvV4PX331FQaDAZaXl3F4eIhe76L79uzsLJaWllAsFrGwsICpqam3DNMkr+mweeszrNA2OTmJ09PTt27dW2bH2565ELNTUrAVDD2OwPCkZ2V+xdxTqVRM2pPU8aR15N9FOnY/Fv6Gf89j+vq+twl8JCjtAVW/xsbGsLi4iHQ6jaWlJXMqscXl7OyshUWEdHRddy+1k+bsx5TJZDA1NWUdTm6Z/T1JkQyGxdJ55EtJ8PP8m7cC8AavpkFIFUYTstmhm9CdxosohaA3kg+LDalDagQTg1dfAhEnHgiN3FSVTV+Logi5XA7j4+MoFAqGxkRRFENbaC/4G4meXPXgXhaG5GeJ5Z+cnOD09DSW5XTL7AEKMQb12n7/omZKs9lEq9WKhbmGpKs+C8BCg9nenR35+BwriDWbTSucpCXh+DnvDdX3/FySHEKMg2HZDk0v9BGXITjSx6GkUikLkmMIBWFAvhZFkdWr1Of4nbyFknwMfq7eHmFwHvvY6trfMjvCSRHeXU4JQSyapa3Hx8dj+ZeMzaCUJNMQYWENmkwmSixqPwAACIlJREFUE8t04vODwSDW5Lder8egTpLPCeXzHmpU55OfJ5Ge09NTsxU4Hp1/iOmGOYB6vZ6V/aZ0Z515Qo+aJabf4UvXDWN4Va94OHhr0ki9VWMuQV4KMmGDiQZk9nw+bx7BkFTVjnxaAYzJHf5Q0eDj7VGv140ZScMke2jsIZQjiiKTwsTKG42G3SjA8Hrv3tAFYHBjvV63xBRmIJ2fn1u7+aRD4g99iLyq6IPlaDhToutv3TK7kF6LITWG1z4DqOr1OtrttmXFU7JkMhnrTsHn+UdDZL1hDMAkH6uC1Wo1a2fjwwsuY7gmURRF1myhWq3i+PgYGxsbqNfr+Pzziypg+Xz+recYGkHqdrs4OjrCzs4Odnd3UalUUK/XY1XStFs4VUGFMDV82kOcOteQI8871IbBtbfMjnhZBm6mDwZj44J0Om34OY1UNgijHkwXPBlZCwqpJ5UHS6UP81eBC2OVQWXD0B8gfHBCpHOcmprC7Oys9Xzd3NzE5uYmvv32W/udXC4HADF0iAf6/Pwc1WoVpVIJ6+vr2NzcxM7ODtrtNqanp7G0tGQ1MLPZrNkmdLINM3S9euYrKCTNMwkJA14z+2Us3ptAujDK7Ior09NITyn1RZJHGNQ4pIrCTdb4Gr6v+jITvRkurHErIbiTTKy+AoXw9DVK3fPzc+vqXS6Xsb+/b9J6enoak5OTsahJ1rkh9t5oNHBycoJqtYpGowEAmJmZQbFYxJdffonFxUWL2ef30EDVxBaOjZ7WJOkdMrT9enAttHYncCvZY6QMo0TprG1p6DDytwAPjOZTqtGlSAM3mZKesBwZn+X2mElEWNAbofq7Xhp6LJ3fzfmwyx/bXFYqFbx48QJbW1vmhh8bG8P4+DgA2I1G4zOVukgr5C0xPz9vddzZKpO6OgAz3jl2Velo1IcSudUg130J2Sx+H0yye2eHbnzoJH2K5CWtLqCWfSOzR9GFJ7XZbL6FgasU53d5xvQb5teXB6RWq2Fvbw/z8/Mx55OiEOqk8r8RQpn86/RuapbW/v6+5dTyZuFB4QFi8zNfLWBxcRELCwsoFAqYmZmx9js6Bi0/ra/7OSj5vdFQ69AtoMIkyOwey0364U+RdDEV91UvnEocog5a4xF4OzCMr73rt3XteaharRZqtRoWFhZiFcEosQaDgY3HY+kehRmGyuRyOaTTaeTzeaysrODw8BAHBweoVCqoVqtoNpsWGPbZZ58hm81a+Y98Pm+J09ls1hJAKBRCB1krAvv3Qvi6Fxg6fz5DUmbnc4mBYCFdkAs8zNL92EhPfNJ1GFJruHisOKCS3Qcq+e9SUintvaGZTMYq51LC+sZh1P9D3/k+a8D9JOY/NTWFQqGAk5MTHB4e4vDwEI1Gw1QWOm1yuRympqbMgUOkKpSQ4seYNM4QnOnHSgqpNWqUBjH8kPULxKUNHQ4A3qua7P938kU5NQHCX7W6kBqs5fHvy8KB3AwPvQEXFbOKxSL+/fdfVKtVazZ8dnZmjcZGRkbeOohXgSKViah/3717FxMTE5ibm4slZFPPJ46t0ZIfUgjqmnhvtAoJ/z4Qv/U8X8cke5L0SToQHzN5HVEPN1/X0g78HDeZ6osXEFchr8ZMTk5arcVer4dGo2HwIOvQhBjsQ+wN1TjCp/8XpPuRhLz4vQHejtz0tuhI0glR8nrRp0Le4g/NUz/Da3psbAy9Xi8WZHRV8rr0YDDAxMSEVebqdDo4OjrC7u6uoRt8LskTeVVS6O99D+4wj+5V6F3qTqikIGNz6JijzWXQo8Jf9Nhls9nEsNBPiZL06hCKoY0DSHyN9ow6fi77+2oTAbDMJsZ2nJ+fo16vY3d3F3t7e9bmnVDkh7h1aYcwbIDQpI9/8c4aLyhDxvl1yfMg/+89pgy7ZuAc4Vx1Wo0wxLPdbqNSqeD58+d2falOqSf3Y1dl1Fr3MKNa+FwoMkO5XDZ1goJhZ2cHuVzOcPGrkKIGTPCo1Wp2uJrNJsrlMkqlEqanp2Mbys0Owcfvux4hNET3X/kAeHO7qI2jSSfX5ROFD6myKFLmD1m320W1WsX+/j6azaa9Z2gMs03Oz89xfHyM7e1ta/akk9XovY+d2YE4Hs75qMHKwviaa1qpVNBsNg0Z6XQ6qFarePnypW30VcbBNeU637lzB61WC/1+H5lMBlF00XirUqlgZ2fH6r2Q2b1Ael8iI/E24WvK4HSSeQSLNowmt2jzhesQmVvVKwpnPxY6+lggqdvtWtqfRT3yNPf7fTQaDezt7ZlU8384gE+NyPiKXdO1zUUeGRmx7BdtI3N8fGybeh1mA95sLqXUnTt3sLCwYK511oBnIBoP3YdQNVVKc0yhOBOvPqhRGEVRLKz5uuOhSuTzd7lXyuwUTkdHR2i328hms1a6w3qpMo2p1WrZl2gZAt0Ivv8pkMfZ9bqjW56f0UwjNhvQGHfWSbnqOLRVOzet1+thZmYGDx48iLWfjKLI6kpSzaHqdR1B5IWa0jB7IOQn+BACkbymhqbynx5Aj2aNjIyYv2B6etrK7I0Ui0UrgcCN9QYJJZs/UZ8aee8br3DGog8GAwv+onS/rmQls1N6K7Orn4PoD8OG2aLS9FHx7r7PeLy66nVyIJ6ooYzv1ZyQR/Oqa6I2BOOQOE/1fVDiM06ejr6JiQnk83nk83lj9qjf7w/osCCqoAYaN5tXgS7wx0x+47znDXjjoKAU15ACMlZSjuhlx6DMzswaGnlM9Oj3+7Y/VDlpoHI8Wi7vqocvpPerquJvD9XlfUWy64yDQodOK0ZbArDXdO0AxAL01KnEBJUoihANXo9IP6QeOuqOimt+KnBk6GrWualhzs0OPXNd1U49qKlUyrDhUJVbjjFkoF1XffAqSZL3MvScCorrjkNtJ6qXKtmV2QkK+MrK2iyB4/kfUEORjHKcErEAAAAASUVORK5CYII=" /></td></tr><tr><td style="text-align:center; width:249px">1</td><td style="text-align:center; width:250px">2</td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>رُج جيدًا قبل الاستخدام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدر غطاء الزجاجة لنزعه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد نزع الغطاء، إذا كان عنق غطاء العبوة غير محكم، قم بإزالته قبل استخدام المنتج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك الزجاجة مع توجيهها لأسفل بين إبهامك وأصابعك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بإمالة رأسك للخلف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسحب جفنك السفلي لأسفل بإصبع نظيف، حتى يظهر &quot;جيب&quot; بين الجفن والعين.&nbsp; ستذهب القطرة في هذا الجيب (صورة 1).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرِّب طرف الزجاجة إلى عينك.&nbsp; قم بذلك أمام مرآة إذا كان هذا سيُساعدك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تلمس عينك أو جفنك أو المناطق المحيطة بهما أو أسطح أخرى بالقطَّارة.&nbsp; فقد يلوث هذا القطرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضغط برفق على الجزء السفلي من الزجاجة؛ لإخراج قطرة واحدة من عقار نيفاناك في المرة الواحدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تضغط بقوة على الزجاجة: فهي مُصممة؛ بحيث لا تحتاج إِلَّا للضغط برفق على الجزء السفلي (صورة 2).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تستخدم القطرة في كلتا العينين، قم بتكرار الخطوات على العين الأخرى. أغلق غطاء الزجاجة بإحكام فورًا بعد استخدامها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تدخل القطرة عينيك، كرر المحاولة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال استخدام قطرات عين أخرى، انتظر على الأقل لخمس دقائق بين استخدام عقار نيفاناك والقطرات الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الجرعة الزائدة من عقار نيفاناك</strong></p><p dir="RTL">اشطف عينك بالماء الدَّافئ. لا تدخل المزيد من القطرات إلى عينيك حتى يحين موعد الجرعة المعتادة التَّالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; <strong>نسيان استخدام عقار نيفاناك</strong></p><p dir="RTL">استخدم جرعة واحدة فور تذكرك للجرعة التي أغفلتها. إذا كان قد حان موعد الجرعة التَّالية تقريبًا، فاترك الجرعة التي أغفلتها واستمر في استعمال الجرعة التَّالية وفقًا للجدول المعتاد. <strong>لا</strong> تستخدم جرعة مضاعفة لتعويض الجرعة التي نسيتها. <strong>لا تستخدم </strong>&nbsp;أكثر من قطرة واحدة في العين المصابة أو العينين المصابتين ثلاث مرات يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. التوقف عن استخدام عقار نيفاناك </strong></p><p dir="RTL">لا تتوقف عن استخدام عقار نيفاناك بدون التَّحدث مع طبيبك أولًا. يمكنك عادة مواصلة استخدام قطرات العين، ما لم تواجه آثارًا جانبية خطيرة. إذا ساورك الشَّك، تحدَّث إلى الطبيب أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي أو الممرض(ة).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون أكثر عرضة للإصابة بالآثار الجانبية في القرنية (مشاكل في سطح العين) في الحالات التَّالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت قد خضعت لجراحة معقدة بالعين.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت قد خضعت لجراحات متكررة بالعين في غضون فترة زمنية قصيرة.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك بعض الاضطرابات في سطح العين كالتهاب أو جفاف العين.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>بعض الأمراض العامة مثل: السكري، أو التهاب المفاصل الروماتويدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك على الفور إذا ازداد احمرار أو ألم عينيك أثناء استخدام القطرة. قد يكون هذا بسبب التهاب سطح العين المصحوب أو غير المصحوب بموت أو تلف خلايا أو بسبب التهاب الجزء الملون من العين (الْتِهاب القُزَحِيَّة). لُوحظت هذه الآثار الجانبية في عدد يصل إلى شخص واحد من بين كل 100 شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لُوحظت الآثار الجانبية التَّالية أيضًا مع عقار نيفاناك 1 مجم/ مللي لتر محلول قطرة عين معلق، أو مع عقار نيفاناك 3 مجم/ مللي لتر محلول قطرة عين، معلق، أو مع كليهما.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبيَّة غير الشَّائعة </strong></p><p dir="RTL"><em>(</em><em>قد تُؤثر في ما يصل إلى </em><em>1 </em><em>من كل </em><em>100&nbsp;</em><em>شخص</em><em>) </em></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التَّأثيرات في العين</strong><strong>: </strong>التهاب سطح العين المصحوب أو غير المصحوب بموت أو تلف الخلايا، أو شعور بجسم غريب في العينين، أو تقشر الجفن أو ارتخائه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبيَّة نادرة </strong></p><p dir="RTL"><em>(</em><em>قد تُؤثر في ما يصل إلى </em><em>1 </em><em>من كل </em><em>1,000&nbsp;</em><em>شخص</em><em>) </em></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التَّأثيرات في العين</strong><strong>:</strong> التهاب القزحية، ألم بالعين، شعور بعدم راحة في العين، جفاف العين، تورم الجفن، تهيج العين، حكة بالعين، إفرازات من العين، التهاب الملتحمة التَّحسسي (حساسية بالعين)، زيادة إفراز الدموع، ترسبات على سطح العين أو وجود سوائل أو تورم بالجزء الخلفي من العين، أو احمرار بالعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الآثار الجانبية العامة</strong><strong>:</strong> دوخة، صداع، أعراض حساسية (تورم ناجم عن حساسية بالجفن)، غثيان، التهاب الجلد، احمرار وحكة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية بمعدل تكرار غير معروف</strong> (لا يمكن تقديره من واقع البيانات المتاحة).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التَّأثيرات في العين</strong><strong>:</strong> ضرر بسطح العين مثل: ترققه أو انثقابه، أو قصور في الالتئام بالعين، أو ندبة بسطح العين، أو تعتيم بالرؤية، أو ضعف الإبصار، أو تورم العين، أو عدم وضوح الرؤية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الآثار الجانبية العامة</strong><strong>: </strong>قيء، ارتفاع ضغط الدَّم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على الزجاجة والعبوة الكرتونية بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقم بالتَّخزين في درجة حرارة تتعدى 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تخلص من الزجاجة بعد 4 أسابيع من فتحها لأول مرة لمنع العدوى. دَوِّن تاريخ فتح الزجاجة عليها وعلى ملصق العبوة الكرتونية في المساحة المخصصة لذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها.&nbsp; ستُساعد هذه الإجراءات في الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL">المادة الفعالة هي: نيبافيناك. يحتوي كل مللي لتر من المحلول المعلق على 1 مجم من نيبافيناك.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><ul><li dir="RTL">المكونات الأخرى هي كلوريد البنزالكونيوم (انظر قسم 2)، وكاربومير، وإديتات ثنائي الصوديوم، ومانيتول، وماء منقى، وكلوريد الصوديوم وتيلوكسابول.</li></ul><p dir="RTL">تمت إضافة كميات صغيرة من هيدروكسيد الصوديوم و/أو حمض الهيدروكلوريك؛ للحفاظ على مستوى حمضية العقار عند المستوى الطبيعي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار نيفاناك هو سائل (معلق ذو لون أصفر فاتح مائل إلى البرتقالي الفاتح) يتوفر في عبوة تحتوي على زجاجة بلاستيكية بحجم 5 مللي لتر مزودة بغطاء لولبي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><br />مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.<br />www.Novartis.com&nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌أ.	تم اعتماد هذه النَّشرة من قبل منظمة الأدوية الأوروبية في: 05/17 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NEVANAC 1 mg/ml eye drops, suspension 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
1 ml of suspension contains 1 mg nepafenac.

Excipient(s) with known effect: 
Each ml of suspension contains 0.05 mg of benzalkonium chloride. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, suspension 
Light yellow to light orange uniform suspension, pH 7.4 (approximately).


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NEVANAC 1 mg/ml is indicated in adults for:</p><p>- Prevention and treatment of postoperative pain and inflammation associated with cataract surgery</p><p>- Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients (see section 5.1)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p><u>Adults, including the elderly</u></p><p>For the prevention and treatment of pain and inflammation, the dose is 1&nbsp;drop of NEVANAC in the conjunctival sac of the affected eye(s) 3&nbsp;times daily beginning 1&nbsp;day prior to cataract surgery, continued on the day of surgery and for the first 2 weeks of the postoperative period. Treatment can be extended to the first 3&nbsp;weeks of the postoperative period as directed by the clinician. An additional drop should be administered 30&nbsp;to 120&nbsp;minutes prior to surgery.</p><p>&nbsp;</p><p>For the reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients, the dose is 1&nbsp;drop of NEVANAC in the conjunctival sac of the affected eye(s) 3&nbsp;times daily beginning 1&nbsp;day prior to cataract surgery, continued on the day of surgery and up to 60&nbsp;days of the postoperative period as directed by the clinician. An additional drop should be administered 30&nbsp;to 120&nbsp;minutes prior to surgery.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Patients with renal or hepatic impairment</em></p><p>NEVANAC has not been studied in patients with hepatic disease or renal impairment.&nbsp; Nepafenac is eliminated primarily through biotransformation and the systemic exposure is very low following topical ocular administration. No dose adjustment is warranted in these patients.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of NEVANAC in children and adolescents have not been established. No data are available. Its use is not recommended in these patients until further data become available.</p><p>&nbsp;</p><p><em><u>Geriatric population</u></em></p><p>No overall differences in safety and effectiveness have been observed between elderly</p><p>and younger patients.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>For ocular use.</p><p>&nbsp;</p><p>Patients should be instructed to shake the bottle well before use. After cap is removed, if tamper evident snap collar is loose, remove before using product.</p><p>&nbsp;</p><p>If more than one&nbsp;topical ophthalmic medicinal product is being used, the medicinal product must be administered at least 5&nbsp;minutes apart. Eye ointments should be administered last.</p><p>&nbsp;</p><p>To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.&nbsp; Patients should be instructed to keep the bottle tightly closed when not in use.</p><p>&nbsp;</p><p>If a dose is missed, a single drop should be applied as soon as possible before reverting to regular routine. Do not use a double dose to make up for the 1 missed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 

Hypersensitivity to other nonsteroidal anti-inflammatory drugs (NSAIDs).

Patients in whom attacks of asthma, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDs.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The product should not be injected. Patients should be instructed not to swallow NEVANAC.</p><p>&nbsp;</p><p>Patients should be instructed to avoid sunlight during treatment with NEVANAC.</p><p>&nbsp;</p><p><u>Ocular effects</u></p><p>Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation (see section 4.8). These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of NEVANAC<sup> </sup>and should be monitored closely for corneal health.</p><p>&nbsp;</p><p>Topical NSAIDs may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. Therefore, it is recommended that caution should be exercised if NEVANAC is administered concomitantly with corticosteroids, particularly in patients at high risk for corneal adverse reactions described below.</p><p>&nbsp;</p><p>Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g. dry eye syndrome), rheumatoid arthritis or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse reactions which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Prolonged use of topical NSAIDs may increase patient risk for occurrence and severity of corneal adverse reactions.</p><p><u>&nbsp;</u></p><p>There have been reports that ophthalmic NSAIDs may cause increased bleeding of ocular tissues (including hyphaemas) in conjunction with ocular surgery. NEVANAC should be used with caution in patients with known bleeding tendencies or who are receiving other medicinal products which may prolong bleeding time.</p><p>&nbsp;</p><p>An acute ocular infection may be masked by the topical use of anti-inflammatory medicines. NSAIDs do not have any antimicrobial properties. In case of ocular infection, their use with anti-infectives should be undertaken with care.</p><p>&nbsp;</p><p><u>Contact lenses</u></p><p>Contact lens wear is not recommended during the postoperative period following cataract surgery. Therefore, patients should be advised not to wear contact lenses unless clearly indicated by their doctor.</p><p>&nbsp;</p><p><u>Benzalkonium chloride</u></p><p>NEVANAC contains benzalkonium chloride which may cause irritation and is known to discolour soft contact lenses. If contact lenses need to be used during treatment, patients should be advised to remove contact lenses prior to application and wait at least 15 minutes before reinsertion.</p><p>&nbsp;</p><p>Benzalkonium chloride has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Since NEVANAC contains benzalkonium chloride, close monitoring is required with frequent or prolonged use.</p><p>&nbsp;</p><p><u>Cross-sensitivity</u></p><p>There is a potential for cross-sensitivity of nepafenac to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro</em> studies have demonstrated a very low potential for interaction with other medicinal products and protein binding interactions (see section 5.2).</p><p>&nbsp;</p><p><u>Prostaglandin analogues</u></p><p>There are very limited data on the concomitant use of prostaglandin analogues and NEVANAC. Considering their mechanism of action, the concomitant use of these medicinal products is not recommended.</p><p>&nbsp;</p><p>Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. Concomitant use of NEVANAC with medications that prolong bleeding time may increase the risk of haemorrhage (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Nevanac should not be used by women of child bearing potential not using contraception.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>There are no adequate data regarding the use of nepafenac in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Since the systemic exposure in non-pregnant women is negligible after treatment with Nevanac, the risk during pregnancy could be considered low. Nevertheless, as inhibition of prostaglandin synthesis may negatively affect pregnancy and/or embryonal/foetal development and/or parturition and/or postnatal development. NEVANAC is not recommended during pregnancy.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>It is unknown whether nepafenac is excreted in human milk. Animal studies have shown excretion of nepafenac in the milk of rats. However, no effects on the suckling child are anticipated since the systemic exposure of the breastfeeding woman to nepafenac is negligible. NEVANAC can be used during breastfeeding.</p><p>&nbsp;</p><p><u>Fertility </u></p><p>There are no data on the effect of NEVANAC on human fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NEVANAC has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>In clinical studies involving 2314&nbsp;patients receiving NEVANAC 1 mg/ml the most common adverse reactions were punctate keratitis, foreign body sensation and eyelid margin crusting which occurred in between 0.4% and 0.2% of patients.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions are classified according to the following convention: very common (&ge;1/10), common (&ge;1/100&nbsp;to&nbsp;&lt;1/10), uncommon (&ge;1/1,000&nbsp;to&nbsp;&lt;1/100), rare (&ge;1/10,000&nbsp;to&nbsp;&lt;1/1,000), very rare (&lt;1/10,000), or not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. The adverse reactions were obtained from clinical trials and post-marketing reports.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ classification</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><em>Rare:</em> hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p><em>Rare: </em>dizziness, headache</p><p><em><s>&nbsp;</s></em></p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p><em>Uncommon</em>: keratitis, punctate keratitis, corneal epithelium defect, foreign body sensation in eyes, eyelid margin crusting</p><p>&nbsp;</p><p><em>Rare</em>: iritis, choroidal effusion, corneal deposits, eye pain, ocular discomfort, dry eye, blepharitis, eye irritation, eye pruritus, eye discharge, allergic conjunctivitis, increased lacrimation, conjunctival hyperaemia</p><p>&nbsp;</p><p><em>Not known</em>: corneal perforation, impaired healing (cornea), corneal opacity, corneal scar, reduced visual acuity, eye swelling, ulcerative keratitis, corneal thinning, blurred vision</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p><em>Not known: </em>blood pressure increased</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p><em>Rare: </em>nausea</p><p><em>Not known:</em> vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><em>Rare: </em>cutis laxa (dermatochalasis), allergic dermatitis</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><em>Diabetic patients</em></p><p>In the two clinical studies involving 209 patients, diabetic patients were exposed to NEVANAC treatment for 60 days or greater for the prevention of macular oedema post cataract surgery. The most frequently reported adverse reaction was punctate keratitis which occurred in 3% of patients, resulting in a frequency category of common. The other reported adverse reactions were corneal epithelium defect and allergic dermatitis which occurred in 1% and 0.5% of patients, respectively both adverse reactions with a frequency category of uncommon.</p><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Clinical trial experience for the long-term use of NEVANAC for the prevention of macular oedema post cataract surgery in diabetic patients is limited. Ocular adverse reactions in diabetic patients may occur at a higher frequency than observed in the general population (see section 4.4).</p><p>&nbsp;</p><p>Patients with evidence of corneal epithelial breakdown including corneal perforation should immediately discontinue use of NEVANAC<sup> </sup>and should be monitored closely for corneal health (see section&nbsp;4.4).</p><p>&nbsp;</p><p>From post-marketing experience with NEVANAC, cases reporting corneal epithelium defect/disorder have been identified. Severity of these cases vary from non serious effects on the epithelial integrity of the corneal epithelium to more serious events where surgical interventions and/or medical therapy are required to regain clear vision.</p><p>&nbsp;</p><p>Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (eg, dry eye syndrome), rheumatoid arthritis or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse reactions which may become sight threatening. When nepafenac is prescribed to a diabetic patient post cataract surgery to prevent macular oedema, the existence of any additional risk factor should lead to reassessment of the foreseen benefit/risk and to intensified patient monitoring.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of NEVANAC in children and adolescents have not been established.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;Saudi Arabia:</p><p>- The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No toxic effects are likely to occur in case of overdose with ocular use, nor in the event of accidental oral ingestion.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Opthalmologicals, Anti-inflammatory agents, non-steroids, ATC code:&nbsp; S01BC10</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Nepafenac is a non-steroidal anti-inflammatory and analgesic prodrug. After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, a nonsteroidal anti-inflammatory drug. Amfenac inhibits the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.</p><p><u>&nbsp;</u></p><p><u>Secondary pharmacology</u></p><p>In rabbits, nepafenac has been shown to inhibit blood‑retinal‑barrier breakdown, concomitant with suppression of PGE<sub>2</sub>&nbsp;synthesis. <em>Ex vivo</em>, a single topical ocular dose of nepafenac was shown to inhibit prostaglandin synthesis in the iris/ciliary body (85%‑95%) and the retina/choroid (55%) for up to 6&nbsp;hours and 4&nbsp;hours, respectively.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>The majority of hydrolytic conversion is in the retina/choroid followed by the iris/ciliary body and cornea, consistent with the degree of vascularised tissue.</p><p>&nbsp;</p><p>Results from clinical studies indicate that NEVANAC eye drops have no significant effect on intraocular pressure.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety </u></p><p>&nbsp;</p><p><u>Prevention and treatment of postoperative pain and inflammation associated with cataract surgery.</u></p><p>Three&nbsp;pivotal studies were conducted to assess the efficacy and safety of NEVANAC dosed 3&nbsp;times daily as compared to vehicle and/or ketorolac trometamol in the prevention and treatment of postoperative pain and inflammation in patients undergoing cataract surgery. In these studies, study medication was initiated the day prior to surgery, continued on the day of surgery and for up to 2‑4&nbsp;weeks of the postoperative period. Additionally, nearly all patients received prophylactic treatment with antibiotics, according to clinical practice at each of the clinical trial sites.</p><p><u>&nbsp;</u></p><p>In two&nbsp;double-masked, randomised vehicle-controlled studies, patients treated with NEVANAC had significantly less inflammation (aqueous cells and flare) in the early postoperative period through the end of treatment than those treated with its vehicle.</p><p>&nbsp;</p><p>In one&nbsp;double-masked, randomised, vehicle and active-controlled study, patients treated with NEVANAC had significantly less inflammation than those treated with vehicle. Additionally, NEVANAC was non-inferior to ketorolac 5&nbsp;mg/ml in reducing inflammation and ocular pain, and was slightly more comfortable upon instillation.</p><p>&nbsp;</p><p>A significantly higher percentage of patients in the NEVANAC group reported no ocular pain following cataract surgery compared to those in the vehicle group.</p><p><strong>&nbsp;</strong></p><p><u>Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.</u></p><p>Four&nbsp;studies (two&nbsp;in diabetic patients and two&nbsp;in non-diabetic patients) were conducted to assess the efficacy and safety of NEVANAC for the prevention of postoperative macular oedema associated with cataract surgery. In these studies, study medication was initiated the day prior to surgery, continued on the day of surgery and for up to 90&nbsp;days of the postoperative period.</p><p><u>&nbsp;</u></p><p>In 1&nbsp;double-masked, randomised vehicle-controlled study, conducted in diabetic retinopathy patients, a significantly greater percentage of patients in the vehicle group developed macular oedema (16.7%) compared to patients treated with NEVANAC (3.2%). A greater percentage of patients treated with vehicle experienced a decrease in BCVA of more than 5&nbsp;letters from day 7&nbsp;to day 90&nbsp;(or early exit) (11.5%) compared with patients treated with nepafenac (5.6%). More patients treated with NEVANAC achieved a 15&nbsp;letter improvement in BCVA compared to vehicle patients, 56.8% compared to 41.9%. respectively, p=0.019.</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with NEVANAC in all subsets of the paediatric population in prevention and treatment of post operative pain and inflammation associated with cataract surgery and prevention of post surgical macular oedema (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following 3&nbsp;times daily dosing of NEVANAC eye drops in both eyes, low but quantifiable plasma concentrations of nepafenac and amfenac were observed in the majority of subjects 2&nbsp;and 3&nbsp;hours post‑dose, respectively. The mean steady-state plasma C<sub>max</sub> for nepafenac and for amfenac were 0.310&nbsp;&plusmn;&nbsp;0.104&nbsp;ng/ml and 0.422&nbsp;&plusmn;&nbsp;0.121&nbsp;ng/ml, respectively, following ocular administration.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Amfenac has a high affinity toward serum albumin proteins. <em>In vitro,</em> the percent bound to rat albumin, human albumin and human serum was 98.4%, 95.4% and 99.1%, respectively.</p><p>&nbsp;</p><p>Studies in rats have shown that radioactive labelled active substance-related materials distribute widely in the body following single and multiple oral doses of <sup>14</sup>C‑nepafenac.</p><p>&nbsp;</p><p>Studies in rabbits demonstrated that the topically administered nepafenac is distributed locally from the front of the eye to the posterior segments of the eye (retina and choroid).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Nepafenac undergoes relatively rapid bioactivation to amfenac via intraocular hydrolases. Subsequently, amfenac undergoes extensive metabolism to more polar metabolites involving hydroxylation of the aromatic ring leading to glucuronide conjugate formation. Radiochromatographic analyses before and after &beta;-glucuronidase hydrolysis indicated that all metabolites were in the form of glucuronide conjugates, with the exception of amfenac. Amfenac was the major metabolite in plasma, representing approximately 13% of total plasma radioactivity. The second most abundant plasma metabolite was identified as 5-hydroxy nepafenac, representing approximately 9% of total radioactivity at C<sub>max</sub>.</p><p><strong>&nbsp;</strong></p><p>Interactions with other medicinal products: Neither nepafenac nor amfenac inhibit any of the major human cytochrome P450&nbsp;(CYP1A2, 2C9, 2C19, 2D6, 2E1&nbsp;and 3A4) metabolic activities <em>in vitro</em> at concentrations up to 3000&nbsp;ng/ml.&nbsp; Therefore, interactions involving CYP‑mediated metabolism of concomitantly administered medicinal products are unlikely. Interactions mediated by protein binding are also unlikely.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>After oral administration of <sup>14</sup>C‑nepafenac to healthy volunteers, urinary excretion was found to be the major route of radioactive excretions, accounting for approximately 85% while faecal excretion represented approximately 6% of the dose. Nepafenac and amfenac were not quantifiable in the urine.</p><p>&nbsp;</p><p>Following a single dose of NEVANAC in 25&nbsp;cataract surgery patients, aqueous humour concentrations were measured at 15, 30, 45&nbsp;and 60&nbsp;minutes post-dose. The maximum mean aqueous humour concentrations were observed at the 1&nbsp;hour time-point (nepafenac 177&nbsp;ng/ml, amfenac 44.8&nbsp;ng/ml). These findings indicate rapid corneal penetration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data reveal no special hazard for humans based upon conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.</p><p>&nbsp;</p><p>Nepafenac has not been evaluated in long-term carcinogenicity studies.</p><p>&nbsp;</p><p>In reproduction studies performed with nepafenac in rats, maternally toxic doses&nbsp;&ge;&nbsp;10&nbsp;mg/kg were associated with dystocia, increased postimplantation loss, reduced foetal weights and growth, and reduced foetal survival. In pregnant rabbits, a maternal dose of 30&nbsp;mg/kg that produced slight toxicity in the mothers showed a statistically significant increase in the incidence of litter malformations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol (E421)</p><p>Carbomer</p><p>Sodium chloride</p><p>Tyloxapol</p><p>Disodium edetate</p><p>Benzalkonium chloride</p><p>Sodium hydroxide and/or hydrochloric acid (for pH adjustment)</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.

Discard 4 weeks after first opening.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30˚C.</p><p>For storage conditions after first opening of the medicinal product, see section 6.3</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5&nbsp;ml round low density polyethylene bottle with a dispensing plug and white polypropylene screw cap containing 5&nbsp;ml suspension.</p><p>&nbsp;</p><p>Carton containing 1&nbsp;bottle.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG.
www.Novartis.com 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2017 By EMA.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>